CA2263671A1 - Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect - Google Patents
Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect Download PDFInfo
- Publication number
- CA2263671A1 CA2263671A1 CA002263671A CA2263671A CA2263671A1 CA 2263671 A1 CA2263671 A1 CA 2263671A1 CA 002263671 A CA002263671 A CA 002263671A CA 2263671 A CA2263671 A CA 2263671A CA 2263671 A1 CA2263671 A1 CA 2263671A1
- Authority
- CA
- Canada
- Prior art keywords
- alkylene
- nr9r10
- alkyl
- compounds
- nhr9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F246/00—Copolymers in which the nature of only the monomers in minority is defined
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
Abstract
Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect are disclosed, as well as a process for preparing the same, medicaments which contain these compounds and their use. Vinyl copolymers are disclosed which contain units of formula (I), in which R1 to R5, d, e, f, H, L, A, Y, Z
and B have the meanings indicated in the description. Also disclosed is a process for preparing the same. These compounds are suitable for treating lipid metabolism disturbances.
and B have the meanings indicated in the description. Also disclosed is a process for preparing the same. These compounds are suitable for treating lipid metabolism disturbances.
Description
. CA 02263671 1999-02-18 WO 98/07449 1 PCT/EP97/0404:~
~ ., _ ... , . . . ~
Description Polymeric bile acid absorption inhibitors having simultaneous bile acid 5 adsorber action The invention relates to polymers having bile acid absorption inhibitor and simultaneous bile acid adsorber action, a process for their preparation and 10 the use of these polymers as pharmaceuticals.
Bile acids and their salts are natural detergents and have an important physiological function in fat digestion and fat absorption. As the end products of cholesterol metabolism, they are synthesized in the liver, 15 stored in the gall bladder and released from there as a constituent of the bile into the intestine, where they display their physiological action. The largest part (about 85-90%) of the secreted bile acids (about 1 6g/day) is absorbed again from the intestinal wall via the enterohepatic circulation, chiefly in the terminal ileum, and transported back to the liver, i.e. recycled.20 Only 10-15% of the bile acids are excreted with the feces. In the liver, a reduction in the amount of bile acid can be compensated for up to a certain degree via a control loop system by de novo synthesis of bile acids from cholesterol. A reduction in the liver cholesterol level leads to the increase of the absorption of cholesterol from the blood serum and thus lowers the 25 cholesterol level in the blood serum. Finally, by suppression of bile acid reabsorption by means of suitable inhibitors or bile acid adsorbers, the enterohepatic circulation can thus be interrupted in the intestine and as a result the serum cholesterol level in the blood lowered. Too high a serum cholesterol level is recognized in medicine as serious, since it leads to 30 atherosclerosis and thus increases the risk of cardiac infarct. There are therefore many therapeutic approaches for the treatment of hypercholesterolemia. One of these approaches is the interruption of the enterohepatic circulation. Using this approach, it is furthermore possible to treat all diseases in which an inhibition of bile acid reabsorption in the small ~ CA 02263671 1999-02-18 - intestine appears to be desirable.
The following have been described in the prior art:
a) Polymeric bile acid adsorbers:
Nonabsorbable polymers have been used therapeutically for some time for the binding of bile acids. In particular, insoluble, usually crosslinked polymers, which contain quaternized nitrogen centers and act like anion 10 exchangers, are employed for this purpose. These polymers bind some of the bile acid anions occurring in the intestine by means of mainly ionic interactions and transport them from the intestine. Commercial products of this type contain, for example, the active compounds cholestyramine and colestipol. They are employed, for example, for the therapy of 1 5 hypercholesterolemia.
b) Bile acid absorption inhibitors (receptor blockers):
In addition to the polymeric bile acid adsorbers, the active bile acid absorption inhibition approach has also been pursued. The bile acid 20 receptor sites in the terminal ileum are blocked here by molecules which, analogously to the bile acids, can interact with the receptors, but unlike the bile acids are not absorbed. As a result of this receptor blockade, the bile acids can no longer be absorbed and are then excreted with the feces.
Examples of polymeric bile acid receptor blockers are found in EP 0 549 25 967. Bile acid polymers and oligomers are described therein in which bile acid molecules are linked laterally to a polymer backbone.
. ~
The compounds described in the prior art have the following disadvantages.
a) Polymeric bile acid adsorbers:
1. The disadvantage of all polymeric bile acid adsorbers on the market to date is the high dosage (10-30 g/day; recommended dose in the case of cholestyramine, for example, 12 g/day). In the case of the polymers known to date, the high daily dose is to be attributed to a low binding rate or to a 10 partial rerelease of the adsorbed bile acids in the isotonic intestinal medium.
~ ., _ ... , . . . ~
Description Polymeric bile acid absorption inhibitors having simultaneous bile acid 5 adsorber action The invention relates to polymers having bile acid absorption inhibitor and simultaneous bile acid adsorber action, a process for their preparation and 10 the use of these polymers as pharmaceuticals.
Bile acids and their salts are natural detergents and have an important physiological function in fat digestion and fat absorption. As the end products of cholesterol metabolism, they are synthesized in the liver, 15 stored in the gall bladder and released from there as a constituent of the bile into the intestine, where they display their physiological action. The largest part (about 85-90%) of the secreted bile acids (about 1 6g/day) is absorbed again from the intestinal wall via the enterohepatic circulation, chiefly in the terminal ileum, and transported back to the liver, i.e. recycled.20 Only 10-15% of the bile acids are excreted with the feces. In the liver, a reduction in the amount of bile acid can be compensated for up to a certain degree via a control loop system by de novo synthesis of bile acids from cholesterol. A reduction in the liver cholesterol level leads to the increase of the absorption of cholesterol from the blood serum and thus lowers the 25 cholesterol level in the blood serum. Finally, by suppression of bile acid reabsorption by means of suitable inhibitors or bile acid adsorbers, the enterohepatic circulation can thus be interrupted in the intestine and as a result the serum cholesterol level in the blood lowered. Too high a serum cholesterol level is recognized in medicine as serious, since it leads to 30 atherosclerosis and thus increases the risk of cardiac infarct. There are therefore many therapeutic approaches for the treatment of hypercholesterolemia. One of these approaches is the interruption of the enterohepatic circulation. Using this approach, it is furthermore possible to treat all diseases in which an inhibition of bile acid reabsorption in the small ~ CA 02263671 1999-02-18 - intestine appears to be desirable.
The following have been described in the prior art:
a) Polymeric bile acid adsorbers:
Nonabsorbable polymers have been used therapeutically for some time for the binding of bile acids. In particular, insoluble, usually crosslinked polymers, which contain quaternized nitrogen centers and act like anion 10 exchangers, are employed for this purpose. These polymers bind some of the bile acid anions occurring in the intestine by means of mainly ionic interactions and transport them from the intestine. Commercial products of this type contain, for example, the active compounds cholestyramine and colestipol. They are employed, for example, for the therapy of 1 5 hypercholesterolemia.
b) Bile acid absorption inhibitors (receptor blockers):
In addition to the polymeric bile acid adsorbers, the active bile acid absorption inhibition approach has also been pursued. The bile acid 20 receptor sites in the terminal ileum are blocked here by molecules which, analogously to the bile acids, can interact with the receptors, but unlike the bile acids are not absorbed. As a result of this receptor blockade, the bile acids can no longer be absorbed and are then excreted with the feces.
Examples of polymeric bile acid receptor blockers are found in EP 0 549 25 967. Bile acid polymers and oligomers are described therein in which bile acid molecules are linked laterally to a polymer backbone.
. ~
The compounds described in the prior art have the following disadvantages.
a) Polymeric bile acid adsorbers:
1. The disadvantage of all polymeric bile acid adsorbers on the market to date is the high dosage (10-30 g/day; recommended dose in the case of cholestyramine, for example, 12 g/day). In the case of the polymers known to date, the high daily dose is to be attributed to a low binding rate or to a 10 partial rerelease of the adsorbed bile acids in the isotonic intestinal medium.
2. Low compliance in patients, on account of the fishy odor and unpleasant, sandy taste and the sandy consistency of the powder of the adsorber (e.g. cholestyramine). The present administration form is 15 problematic, since the adsorber powder does not dissolve in water but can only be suspended. To improve compliance, in some cases more than 50% of taste- and odor-improving additives must be added, such that as a result the daily dose of adsorber medicament is further increased.
3. The adsorbers known to date do not act selectively enough and also 20 bind vitamins (e.g. vitamin K) and other physiologically important substances, so deficiency symptoms (e.g. avitaminosis) can occur.
4. A damping action on the cholesterol metabolism of the intestinal bacteria is lacking.
b) Bile acid absorption inhibitors:
1. With all low molecular weight absorption inhibitors known to date, there is the danger of cytotoxic side effects due to absorption in the intestine.
30 Thus pinocytosis and other transport mechanisms for the absorption of these low molecular weight inhibitors cannot be excluded. A nonsystemic action cannot be guaranteed.
2. An unpleasant side effect which can occur with the bile acid absorption inhibitors known to date, because of the increase in the bile acid . . .
concentration in the intestine caused by the receptor blockade, is diarrhea.
Objective of the present invention:
b) Bile acid absorption inhibitors:
1. With all low molecular weight absorption inhibitors known to date, there is the danger of cytotoxic side effects due to absorption in the intestine.
30 Thus pinocytosis and other transport mechanisms for the absorption of these low molecular weight inhibitors cannot be excluded. A nonsystemic action cannot be guaranteed.
2. An unpleasant side effect which can occur with the bile acid absorption inhibitors known to date, because of the increase in the bile acid . . .
concentration in the intestine caused by the receptor blockade, is diarrhea.
Objective of the present invention:
5 It was the object of the present invention to prepare a nonsystemically acting polymeric active compound to interrupt the enterohepatic circulation, which no longer has the abovementioned disadvantages.
The object is achieved by binding bile acid molecules or low molecular 10 weight bile acid absorption inhibitor molecules firmly to a polymer molecule covalently or via a spacer group, such that they are no longer absorbable themselves, but their absorption-inhibiting action is still retained. In this way, the systemic cytotoxic side effects of the low molecular weight absorption inhibitors which occur in some cases and can be caused by 15 their absorption, are avoided. The polymer, for its part, is too large to be absorbed. The polymer additionally contains bile acid adsorber centers, e.g. quaternized nitrogen centers, in the molecule. These reduce the bile acid concentration in the intestine, which is increased by the receptor blockade, by binding and adsorbing bile acid anions.
20 Polymers of this type thus have a dual action. On the one hand, they act as polymeric bile acid absorption inhibitors due to the covalently firmly bonded receptor blocker units and, on the other hand, as bile acid adsorbers.
The invention therefore relates to vinyl copolymers consisting of units of 25 the formula I
~CH2 C3~CCH2--C3~ECH2--c3 L oR4 ~ B
~\1 1 ~~oR5 and their physiologically tolerable salts, in which:
R1, R2, R3 are hydrogen or CH3;
R4, R5 are hydrogen, (C1-C6)-alkyl, (C1-C6)-acyl;
d is 0.01 to 1.00;
e is 0 to 0.99;
f is 0 to 0.99;
where d + e + f must be equal to 1;
L is a bond, -NH-, -N(CH3)-, -+NH2CI--, -+NH(CH3)CI--, -+N(CH3)2CI--, NH-CO-, -NH-(CH2)n-, ~NH-[(cH2)n-o-]m-(cH2)p-~ ~NH~(CH2)n~
-NH-co-(cH2)p-~-NH-(cH2)n-co-NH(cH2)m-N-(cH3)2 Cl~(CH2)m~~
-NH-[CH2-CH(CH3)-O-]m-CH2-CH(CH3)-, -NH-(cH2)m-N(cH3)2 Cl~(CH2)n~~
-O-(CH2)n-, ~~~(CH2)n~C~~~
-CO-, -CO-NH-, -CO-N(CH3)-, -CO-NH-CO-, -CO-NH-(CH2)n-, -CO-NH-[(CH2)n-O-]m-(CH2)p-, -CO-NH-(CH2)n-CO-, -CO-NH-CO-(CH2)n -, -co-NH-[cH2-cH(cH3)-o-]m- CH2-CH(CH3)-' -CO-NH-(CH2)m-+N(CH3)2CI ~(CHZ)n~~
-CO-(CH2)n-O-(CH2)p-CO-, -Ar-, -Ar-CO-, -Ar-CH2-, -Ar-CH2-+N(CH3)2CI ~(CH2)n~~ -CO-Ar-CO-, -(C1 -C1 2)-alkylene-, I
-NH-CH2-Ar-CH2-N ~(CH2)n~~
I
CH3 Cl -NH-Ar-CO-, -NH-CH2-Ar-CH2-, -NH-CO-Ar-CO-;
H is a bond, -CH2-, -Ar-, -Ar-CH2-, where Ar is phenylene, naphthylene;
m is 1 to 18;
n is 1 to 18;
p is 1 to 18;
A is -O-, -NH-, a bond;
B js-oH~-oNal-oK7-NH2~-NH-cH3~-N(cH3)2~-NH-cH2-cH2-SO3Na, -NH-CH2-COONa, -NH-CH2-CH2-+N(CH3)3CI-, -~-(C1 -C18)-alkyl~-NH-(c1-c6)-alkyl~ NH-(C1-C6)-alkYIene-HO
~ ~ ~R7 ~A3H OH
R7 is-OH,-O-(C1-C6)-alkYl~-NH2;
Y is -NH2, -+NH3CI--, -NH-R9, -+NH2R9 Cl--, -NR9R10, -+NR9R10R11 Cl~,-(C1-C18)-alkylene-NH2-,-(C1-C18)-alkylene-+NH3CI~-,-(C1-C18)-alkylene-NHR9, -(C1-C18)-alkylene-NR9R1~, -(C1-C18)-alkylene-+NR9R10R1 1CI-, -NH-CO-(C1-C18)-alkyl, -NH-CO-(C1-C12)-alkylene-N R9R1 ~, -N H-CO-(C1 -C1 2)-alkylene-+N R9R1 0R11 Cl-, -COR9, -CO-, CO NH-(C1-C18)-alkylene-+NR9R1~R11CI~ ph , -phenylene-(CO-C6)- alkylene-NH2, -phenylene-(CO-C6)-alkylene-NH-R9, -phenylene-(C0-C6)-alkylene-NR9R1 ~, -phenylene-(C0-C6)-alkylene- +NR9R10R11CI-, -CO-NH-R9, -NH-(C1-C18)-alkylene-NHR9, -NH-(C1 -C18)-alkylene-NR9R1~, -NH-(C1 -C18)-alkylene-+NR9R10R1 1 Cl-, -COOH, -O-R9, -CONH2, -O-CO-R9, -CO-(Cl-Cl2)-alkyl, -O-CO-(Cl-Cl2)-alkylene-NR9Rl~, -O-CO-(Cl-C12)-alkylene-+NR9R10Rll Cl-, N~N +) F ~ --N/~ ~ --N~3 Cl N~ Cl- , - C - O - C H 2 - C H - C H 2-~ H
-~-NH-(CH2)m-NR9R1 ~
-c-o-(c1-c18)-alkylene-+N-(c1-c18-alkyl)3 Cl-1~ 9 10 -C-O-(C1-C18)-alkylene-NR R
Z is -NH2, -+NH3CI--, -NH-R9, -+NH2R9 Cl--, -NR9R10, -+NR9R10R11 Cl-, -(C1-C18)-alkylene-NH2-, -(C1-C18)-alkylene-+NH3CI -, -(C1-C1g)-alkylene-NHR9,-(C1-C18)-alkylene-NR9R1~,-(C1-C18)-alkylene-+NR9Rl0Rl lCI-, -NH-CO-(Cl -Cl8)-alkyl, -NH-CO-(Cl-Cl2)-alkylene-.
NR9R1~, -NH-CO-(C1-C12)-alkylene-+NR9R1~R1 1CI~, -COR9, -CO-OR9, -CO-NH-(C1-C18)-alkylene-+NR9R1~R1 1CI-, -phenyl, -p h e nyle n e-(C O-C 6)-alkyle n e-N H 2, -p h e nyle n e-(C O-C 6)-alkyle n e-N H-R9, -phenylene-(C0-C6)-alkylene-N R9R1 ~, -phenylene-(C0-C6)-alkylene- +NR9R10R11CI-, -CO-NH-(C1-C12)-alkyl, -NH-(C1-C18)-alkylene-NHR9, -NH-(C1-C18)-alkylene-NR9R1~, -NH-(C1-C18)-alkylene-+NR9R1~R11 Cl-,-COOH, -O-R9, -CONH2, -O-CO-R9, -CO-(C1 -C12)-alkyl, -O-CO-(C1 -C12)-alkylene-NR9R1~, -O-CO-(C1 -C12)-alkylene-+NR9R10R11 Cl---N/~ Cl- /~ + fi~ Cl-\~N(+) ~ --N ' --N~
N~ Cl- , -C -O -C H 2-l H -C H 2-~ H
O
-~-NH-(CH2)m-NR9R1 ~
-C-O-(C,-C,8)-alkylene-N+-(C1-C,8-alkyl)3 Cl, or a crosslinker selected from the group consisting of:
-C~X-(C2-C6)-alkylene-X-CC CR1-CH2-' CA 02263671 1999-02-18 . ~
-(~-(C1 ~c3)~alkYlene)1 -1 8-0-CH-CH2 , -NH-(C1 -C1 2)-alkylene-NH-CH-CH2--NH-cH2-cH(oH)-cH2-NH-TH-cH2-, -NH-CHOH-(C,-C12)-alkylene- CHOH-NH-CH-CH2-X is 0, -NH-;
R9, R10 are (C1-C18)-alkyl-, -phenyl, -CH2-phenyl;
R1 1 is H, (C1 -C1 8)-alkyl-, -phenyl, -CH2-Phenyl;
where at least one of the radicals L, Y and Z must contain an ammonium center.
20 Preferred compounds of the formula I and their physiologically tolerable salts are those in which:
R1, R2, R3 are hydrogen or CH3;
R4, R5 are hydrogen;
d is 0.01 to 1.00;
e isOtoO.99;
f isOtoO.99;
where d+e+f must be equal to 1;
30 L is-NH-,-NH-(C1-C18)-alkylene-, -NH-((C1 -C3)-alkylene-0-)1 -1 8-(C1 -C3)-alkylene-, -CO-NH-, -CO-NH-(C1 -C18)-alkylene-, , - CA 0226367l l999-02-l8 - a~3 a--CaNH-(C1 -C1 8)-alkYIene- ~-(C1 -Cl g)-alkylen~, CH
o Il -CO-, -NH-(C1 -C6)-alkylene-C-NH-;
H is a bond, -CH2-;
A is -O-, a bond, -NH-;
15 B is-OH,-ONa,-OCH3,-NH-CH2-CH2-OCH3, HO \,/~\~
~O~OH
~' ~A~N~J\OH
Y is-NH2,-NHR9,-NR9Rl~,-+NR9R1~R1lCI~,-NH-(C1-C18)-alkylene-+NR9Rl0RllCI-,-CH2-NH2,-CH2-NH-R9,-CH2-NH-(Cl-Cl8)-alkylene-NR9R1~,-CH2-NH-(C1-C18)-alkylene-+NR9R1~R11CI~,-NH-CO-R9, -CO-NH-R9, -CO-NH-propylene-+NR9R10R1 1CI-, ~ +
\~ N
N~
-CO-O-(Cl-Cl8)-alkylene-NR9R1~;
- Z is-NH2,-NHR9,-NR9R1~,-NH-(C1-C18)-alkylene-+N-(CH3)3CI~, -CH2-NH2, -CH2-NH-R9, -CH2-NR9R1~, -CH2-NH-(C1 -C18)-alkylene-+NR9R10R11CI-, or a crosslinker selected from the group consisting of:
-NH(C1 -C1 2)-alkylene-NH-CH-CH2--CO-X-(C2-C18)-alkylene-X-C~CR1-CH2--NH-CH2-CH(OH)-CH2-NH-CH-CH2-;
I
X is-O-,-NH-;
R9, R10, R11 are (C1-C6)-alkyl-, -phenyl, -CH2-phenyl, 15 where at least one of the radicals L, Y and Z must contain an ammonium center.
Particularly preferred compounds of the formula I and their physiologically tolerable salts are those in which:
R1, R2, R3 are hydrogen;
R4, R5 are hydrogen;
d is 0.01 to 1.00;
e isOtoO.99;
f is O to 0.99;
where d+e+f must be equal to 1;
L is-NH-cH2-cH2-o-cH2-cH2-o-cH2-cH2 o -C-NH-(C1 -C1 8)-alkylene-, -NH-(C1 -C1 8)-alkylene-, -CO-, -NH-, .
CA 0226367l l999-02-l8 -C-NH-(C1 -C6)alkYIene-~ -(C1 -C1 8)-alkYIene -(C1 -C6)-alkylene-NH-(C~ -C6)-alkylene-;
H is a bond, -CH2-;
A is -O-, -NH-, a bond;
B is-OH,-ONa,-NH-CH2-CH2-OCH3;
Y is-NH2,-NHR9,-NH-(C1-C18)-alkylene-+N(CH3)3CI~,-CO-NH-(C1-C10)-alkylene-+N(CH3)3CI~, -CO-NH-(C1 -C6)-alkylene-N(CH3), -CH2-NH2,-CH2-NHR9;
Z is-NH2,-NHR9,-CH2-NH2,-CH2NHR9,-NH-(C1-C18)-alkylene-+N-(CH3)3CI~,-CH2-NH-(C1-C18)-alkylene-+N-(CH3)3CI~,-CO-NH-propylene-+N(CH3)3CI~;
where at least one of the radicals L, Y and Z must contain an ammonium center.
25 Physiologically tolerable acid addition salts is understood as meaning readily water-soluble, soluble or sparingly soluble compounds according to the definition in the "German Pharmacopeia" (9th Edition 1986, official edition, Deutscher Apotheker-Verlag Stuttgart), page 19. The hydrochlorides and sulfates of the compounds are preferred.
An ammonium center is understood as meaning a positively charged nitrogen atom (quaternized).
The invention furthermore relates to a process for the preparation of the ' CA 02263671 1999-02-18 . _ .
- polymers consisting of units of the formula 1.
General description of the preparation process of the polymers:
5 The synthesis of the cholate-containing monomers was carried out as described in the examples.
Method 1:
Bonding of a linker to cholic acid and subsequent polymer-analogous 10 reaction with a polymer containing amino groups Cholic acid is first mesylated with methanesulfonyl chloride in basic medium. The mesyl group is a good leaving group and makes possible the addition of side chains, e.g. of a triethylene glycol unit, by nucleophilic 15 substitution. The free hydroxyl group of the triethylene glycol unit is then selectively activated by reaction with tosyl chloride. The tosyl leaving group thus formed makes possible the polymer-analogous reaction with polymers containing amino groups, e.g. polyallylamine or polyvinylamine (Example 1 d). The degree of substitution can be adjusted by changing the 20 polyamine: cholic acid derivative ratio.
Method 2:
Preparation of cholic acid amido ethers and subsequent bonding of a linker and polymer-analogous reaction with polymers containing amino groups Cholic acid is first converted into the active ester using p-nitrophenol. The amido ether is then obtained by reaction with 2-methoxyethylamine (Example 3b). This is linked via a linker to a polymer containing amino groups as described in Method 1.
Method 3:
Free radical copolymerization of acrylic-substituted cholic acid derivatives with vinylic monomers CA 0226367l l999-02-l8 - An acrylic-substituted cholic acid derivative is reacted with a vinylic (preferably acrylic) monomer by free radical copolymerization (see Example 5). Ester groups which may possibly still be present in the cholate radical can be selectively hydrolyzed under basic conditions.
Method 4:
Polymer-analogous reaction of mesyl-substituted cholic acid with polymers containing amino groups Cholic acid mesylate can be directly reacted with polymers containing amino groups, e.g. polyamines, in a polymer-analogous reaction at pH = 8-10. Substituted polyamines can also be employed here (Examples 6, 17).
Method 5 Introduction of a linker group by reaction of cholic acid with dibromoalkanes and subsequent polymer-analogous reaction with polymers containing amino groups In this method, a direct reaction of cholic acids with a dibromoalkane, e.g.
dibromohexane, is achieved in THF in basic medium (Examples 7a, 15). A
large excess of dibromoalkane is important here. The omega-bromoalkoxy cholic acid obtained is then converted into the polymer according to the invention in a polymer-analogous reaction with a polymer containing amino groups, e.g. a polyamine (Examples 7b, 12, 13, 15).
Method 6 Synthesis of a cholic acid derivative with a cationic center in the linker group and subsequent homo- or copolymerization of the monomer 30 obtained 3-(N,N-Dimethylaminopropyl)methacrylamide is reacted with a bromo- or mesyl-substituted cholic acid derivative in a Menschutkin reaction. The 3-amino group is quaternized here and a highly water-soluble acrylate-- substituted cholic acid derivative is produced (Examples 8, 9a). This can be homopolymerized under free radical conditions or copolymerized with other vinylic comonomers (Example 9).
5 Method 7 Free radical copolymerization of acrylic-substituted cholic acid with allylamine (hydrochloride) or another vinylic polymerizable amine Allylamine (hydrochloride) and other vinylic amines which can be 10 polymerized under free radical conditions can be directly polymerized with acrylic-substituted cholic acid derivatives (Examples 11, 16).
Method 8 Polymer-analogous Michael addition of acrylic-substituted cholate to 15 polymers containing amino groups In this reaction, an acrylic-substituted cholic acid derivative is reacted with a polymer containing amino groups, e.g. a polyamine, in alcoholic solution at pH = 9-10 in a Michael addition.
The present invention also relates to pharmaceutical preparations which comprise one or more of the active compounds according to the invention and, if appropriate, further hypolipidemic agents.
25 The active compounds according to the invention are suitable for use as hypolipidemic medicaments.
The active compounds according to the invention are used, for example, as pharmaceutical preparations, foodstuffs additives, formulation 30 auxiliaries, detergents, medicaments for influencing the enterohepatic circulation of the bile acids, medicaments for influencing lipid absorption, medicaments for influencing the serum cholesterol level, medicaments for the concentration-dependent inhibition of bile acid absorption in the gastrointestinal tract or as medicaments for the prevention of ' CA 02263671 1999-02-18 - arteriosclerotic symptoms.
Experimental section:
Example 1:
a) Example 1a: Cholic acid mesylate:
O O
,~OH ,~, J OH
~ ~l ~
O
1a 9.2 ml (117 mmol) of methanesulfonyl chloride were added dropwise at 0~C to 40.9 g (100 mmol) of cholic acid in 200 ml of pyridine in the course of 20 min. The mixture was first stirred at 0~C for 15 min and then at room temperature for 5 h. After standing overnight, the mixture was poured onto 1000 ml of ice water/200 ml of conc. sulfuric acid and stirred for a further 10 min. The resulting precipitate was filtered off with suction and washed with water. The precipitate was then dissolved in methylene chloride and the solution was extracted with water. The organic phase was dried using sodium sulfate and evaporated. The product (Example 1 a) was obtained quantitatively and employed for the subsequent step without further purification.
1H NMR: (CDCI3) o = 0.69 ppm (s, 3H, CH3); 0.91 (s, 3H, CH3); 0.99 (d, J=6.0 Hz, CH3CH), 0.9-2.6 (m, 24 H, aliphat. CH), 2.99 (s, 3H, CH3SO3); 3.87 (br. s, 1 H, CHOH); 4.01 (br. s, 1 H, CHOH); 4.50 (m; 1 H, CHOS02) ' CA 02263671 1999-02-18 Example 1b:
Adduct of triethylene glycol to cholic acid:
OH ,~OH
~~ ~X~ ~HO ~
H3C-S-O OH ~O ~ ~OH
la lb 6.1 9 (12.5 mmol) of Example 1a were suspended in 25 ml (150 mmol) of triethylene glycol and dissolved by briefly heating to 100~C. 4.0 9 (100 mmol) of magnesium oxide were added and the mixture was stirred at 100~C for 5 h. After standing overnight,100 ml of methylene chloride were added and the resulting precipitate was filtered off with suction and washed with methylene chloride. The organic phase was extracted with 200 ml of 2N aq. hydrochloric acid and then concentrated. Crude yield: 7.2 9. The crude material was purified by chromatography on silica gel (gradient ethyl acetate ~ ethyl acetate: methanol = 1: 1). The product fraction was precipitated with methylene chloride with stirring under ultrasound and the precipitate was filtered off. The filtrate contains pure Example 1 b. Yield after concentrating: 1.7 9 (25%) of Example 1 b.
1H NMR: (CDCI3) o = 0.69 ppm (s, 3H, CH3); 0.91 (s, 3H, CH3); 0.99 (d, J=6.0 Hz, CH3CH), 0.8-2.4 (m, 24 H, aliphat. CH); 3.5-3.75 (m,13H, O-CH2-CH2-O and CHR2OCH2); 3.85 (br. s,1 H, CHOH); 3.97 (br. s,1 H, CHOH) .
Example 1c:
~OH ~OH
~ ~ ~
~O~OH TsO~E o~ 'OH
1b 1c 248 mg (1.3 mmol) of tosyl chloride, dissolved in 20 ml of dichloromethane, were added in portions at 0~C in the course of 30 min to 600 mg (1.1 mmol) of Example 1b and 140 mg (2.5 mmol) of potassium hydroxide powder in 30 ml of dichloromethane. Since TLC checking still did not show complete reaction, a further 100 mg (1.8 mmol) of potassium hydroxide powder were added. The mixture was stirred at room temperature for a further 1 h. The resulting precipitate was filtered off. The filtrate was concentrated. Crude yield: 1.3 g. The crude product was dissolved in a little dichloromethane and purified by means of column chromatography on silica gel (ethyl acetate: methanol = 9: 1). Yield: 540 mg (70%).
1H NMR: (CDCI3) o = 0.68 ppm (s, 3H, CH3); 0.90 (s, 3H, CH3); 0.98 (d, J=6.0 Hz, CH3CH), 0.6-2.5 (m, 24 H, aliphat. CH); 2.44 (s, 3H, Ts-CH3);
3.5-3.75 (m,12H, O-CH2-CH2-O); 3.84 (br. s,1H, CHOH); 3.97 (br. s,1H, CHOH); 4.15 (m, 1H, CHR2OCH2); 7.34 (d, J=9Hz, 2H, aryl H), 7.79 (J=9Hz, 2H, aryl H).
~ , .
- CA 0226367l l999-02-l8 Example 1d:
2 I m:n=0.99:0.01 x HCI xHCI
;~ I 011 (~ 1~ 0 Na TsO~ OH
1c 1d 200 mg of polyvinylamine were dissolved in 20 ml of water and pH=10 was set. 66 mg (2 mol%) of 1 c, dissolved in 20 ml of ethanol, were added and pH=10 was again set. The mixture was stirred at 50~C for 6 h, the pH
changing to pH = 8. The pH was again adjusted to pH = 10 and the mixture 10 was allowed to stand ovemight at room temperature. The product 1 d was purified by ultrafiltration (membrane 5000A) using ethanol:water = 1:1 and isolated by freeze-drying of the retentate. Yield: 180 mg. 1 H NMR analysis showed a degree of substitution on the polyvinylamine of n = 1%.
1H NMR (D2O): o = 0.57 ppm (s, 3H, cholate CH3); 0.79 (br. m, 6H, cholate-CH3 and CH3CH); 1.0-1.6 (m, aliphat. cholate CH); 1.6-2.5 (m, CH2-CHNH and aliphat. cholate CH); 3.3-3.5 (O-CH2-CH2-O); 3.5-4.0 (br.
s, CHNH-CH2); 4.0-4.4 (m, CHOH and CHR2OCH2).
- Example 2:
NH2 NH2 NH m: n = 0.95: 0.05 xHa xHa + ~ ~o Na T90'E--o~/
1c 2 0.7 ml of 2N sodium hydroxide solution was added to a solution of 100 mg of polyvinylamine in 20 ml of ethanol and the mixture was warmed to 40-50~C. 496 mg of Example 1 c were added in portions in the course of 6 h.
10 The pH was kept at pH = 9 and the mixture was allowed to stand at room temp. for 3 days. The product 2 was purified by ultrafiltration (5000A
membrane) using ethanol:water = 1:1 and isolated by freeze-drying of the retentate. Yield: 170 mg, 1H NMR analysis showed a degree of substitution on the polyvinylamine of n = 5%.
1H NMR: as Example 1d.
- Example 3:
Example 3a:
O O
~J~OH ~ J1'O~3NO2 5 HO--/~OH HO--~OH
3a 20 g (49 mmol) of cholic acid were dissolved in 300 ml of THF and 10.2 g (73 mmol) of p-nitrophenol and a spatula tipful of p-N,N-dimethylamino-pyridine were added. The mixture was cooled to 0~C and 13.2 g (64 mmol) of dicyclohexylcarbodiimide, dissolved in 50 ml of THF, were then added.
The mixture was stirred at 0~C for 30 min and then at room temp. for 4 h, a precipitate forming. This was filtered off. The filtrate was concentrated to a half of the volume and treated with pentane until it began to get cloudy.
The mixture was stirred for a further 1 h and the resulting precipitate was filtered off. The combined precipitates were washed with toluene and dried.
Yield: 11.5 g. The combined filtrates were evaporated to dryness and the residue was dissolved in 100 ml of THF. The solution was again treated with pentane until it began to get cloudy and stirred for a further 1 h. The resulting precipitate was again filtered off. Yield: 4.5 g.
Total yield of Example 3a: 16.0 g (62%).
1H NMR: (CDCI3) o = 0.70 ppm (s, 3H, CH3); 0.90 (s, 3H, CH3); 1.06 (d, J=6.0 Hz, CH3CH), 0.9-2.8 (m, 24 H, aliphat. CH); 3.47 (br. s,1 H, CHOH); 3.85 (br. s,1 H, CHOH); 3.99 (br. s, 1 H, CHOH); 7.28 (d, J=9Hz, 2H, aryl H), 8.26 (d, J=9Hz, 2H, aryl H).
- Example 3b:
O O
~o~3No2 ~NH~oCH3 HO~OH HO--~OH
3a 3b 750 mg (10 mmol) of 2-methoxyethylamine were initially introduced into a mixture of 100 ml of ethanol and 100 ml of water and 5.9 g (11 mmol) of Example 3a were added in portions, the pH being kept at 10-11 by addition of sodium hydroxide solution. The cloudy mixture was stirred at 40-50~C for 4 h and then allowed to stand at room temp. for 3 days. The mixture was filtered and the filtrate was concentrated to a volume of 50 ml. By addition of hydrochloric acid, the pH was adjusted to pH = 1. The mixture was extracted twice with diethyl ether and then twice with dichloromethane. The ether extracts were discarded. The combined dichloromethane phases were evaporated after drying over sodium sulfate. Yield: 4.4 g (94%) of Example 3b.
1H NMR: (CDCI3) o = 0.68 ppm (s, 3H, CH3); 0.99 (s, 3H, CH3); 1.00 (d, J=6.0 Hz, CH3CH), 0.9-2.4 (m, 24 H, aliphat. CH); 3.36 (s, 3H, CH30);
3.45 (m, 5H, CHOH and NH-CH2-CH2-O); 3.84 (br. s,1 H, CHOH); 3.96 (br.
s,1 H, CHOH); 6.20 (br. s, 1 H, NH) .
~ Example 3c:
~ , ~ ~NH~oCH3 ~ ~ ~
HO OH H3C-S-O~OH
3b 3c 4.1 g (9.9 mmol) of Example 3b were dissolved in 20 ml of pyridine.
0.92 ml of methanesulfonyl chloride were added at 0~C and the mixture was stirred at 0~C for 30 min and at room temp. for 1 h. The mixture was treated with ice. 20 ml of conc. sulfuric acid were then slowly stirred in. The mixture was stirred for a further 5 min. The resulting precipitate was filtered off, washed with water and then taken up in dichloromethane. This solution was extracted with water. The organic phase was evaporated after drying over sodium sulfate.
Crude yield: 4.7 g. The crude product was purified by column chromatography on silica gel (ethyl acetate). Yield: 2.9g (54%) of Example 3c.
1H NMR: (CDCI3) o = 0.69 ppm (s, 3H, CH3); 0.91 (s, 3H, CH3); 1.00 (d, J=6.0 Hz, CH3CH), 0.9-2.4 (m, 24 H, aliphat. CH); 2.99 (s, 3H, CH3SO3); 3.36 (s, 3H, CH30); 3.45 (m, 4H, NH-CH2-CH2-O); 3.86 (br. s, 1 H, CHOH); 3.99 (br. s,1 H, CHOH); 4.50 (br. s,1 H, CHOSO2); 6.05 (br. s, 1H, NH).
.. , ~.. .. .
- Example 3d:
O O
--~NH~OCH3 ~ NH~OCH3 ~l ~X-~ ~ ~/~/
H3C-S-O OH ~O~----OH
3c 3d 1 ml of triethylamine was added to a solution of 2.9 9 (5.3 mmol) of Example 3c and 12.0 9 (80 mmol) of triethylene glycol in 5 ml of dichloromethane. The methylene chloride was distilled off and the mixture was then heated to 100~C. 2 ml of triethylamine were added and the mixture was stirred at 100~C for 5 h.1 ml of triethylamine was then added again and the mixture was stirred at 100~C for a further 8 h. The mixture was allowed to stand at room temp. for 1 week and then dissolved in dichloromethane. The solution was poured into 50 ml of ice water/conc.
sulfuric acid (1:1). This mixture was extracted 3 times with dichloromethane. The organic phase was washed with water, dried over sodium sulfate and evaporated. Crude yield: 2.5 9. The crude material was purified by chromatography on silica gel (gradient ethyl acetate ---> ethyl acetate: methanol = 9:1). Yield: 0.9 9 (30%) of Example 3d.
1H NMR: (CD30D) ~ = 0.70 ppm (s, 3H, CH3); 0.91 (s, 3H, CH3); 1.02 (d, J=6.0 Hz, CH3CH), 0.8-2.5 (m, 24 H, aliphat. CH); 3.25-3.35 (m, 2H, NH-CH2-CH2-O); 3.34 (s, 3H, CH30); 3.41-3.46 (m, 2H, NH-CH2-CH2-O);
3.50-3.67 (m,13H, O-CH2-CH2-O and CHR2OCH2); 3.79 (br. s, 1H, CHOH); 3.95 (br. s,1 H, CHOH).
- Example 3e:
~NH~OCH3 ~,I~NH~~CH3 ~O~ OH TsO~O~OH
3d 3e 900 mg (1.5 mmol) of Example 1d were dissolved in 30 ml of dichloromethane. 343 mg (1.8 mmol) of p-toluenesulfonyl chloride and 140 mg (2.5 mmol) of potassium hydroxide powder were added to this solution at 0~C. The mixture was warmed to room temp. with stirring. After stirring at room temp. for30 min,100 mg (1.8 mmol) of potassium hydroxide powder were again added and the mixture was again stirred for 2 h. The precipitate was filtered off. The filtrate was evaporated. Crude yield: 1.2 g. Pure Example 3e was obtained by column chromatography on silica gel (gradient dichloromethane ---> dichloromethane: methanol = 95:
5). Yield: 870 mg (77%) of 3e.
1H NMR: (CDCI3) o = 0.69 ppm (s, 3H, CH3); 0.90 (s, 3H, CH3); 0.98 (d, J=6.0 Hz, CH3CH),1.0-2.4 (m, 24 H, aliphat. CH); 2.45 (s, 3H, Ts-CH3);
3.36 (s, 3H, CH30); 3.4-3.65 (m,13H, O-CH2-CH2-O, NH-CH2-CH2-O and CHR2OCH2); 3.70 (t, J= 6Hz, 2H, Ts-O-CH2-CH2); 3.84 (br. s,1 H, CHOH);
3.97 (br. s,1H, CHOH); 4.16 (t, J= 6Hz, 2H, O-CH2-CH2); [lacuna]
1 H, CHR2OCH2); 7.35 (d, J=9Hz, 2H, aryl H), 7.80 (d, J=9Hz, 2H, aryl H).
- Example 3f:
2 I m:n=0.99:0.01 x HCI x HCI
--Jl'hH ~NH
~/~/ OCH3 <~)0 ~~/~/ OCH3 TsO~o~J'OH
5 150 mg of polyvinylamine were dissolved in a mixture of 20 ml of water and 20 ml of ethanol. pH = 10 was set.131 mg (5 mol%) of Example 3e were added in portions at 40-50~C. The solution was stirred at room temp. for 4 h and then heated under reflux for 3 h. After allowing to stand for a further 3 days, Example 3e was still detectable. The mixture was adjusted 10 to pH = 12 and then heated under reflux for a further 7 h. After cooling, thepolymeric product was isolated by ultrafiltration (5000A membrane;
ethanol/water = 1 :1) and subsequent freeze-drying. Yield: 180 mg of Example 3f. The 1H NMR analysis showed a degree of substitution of about n = 1 %.
1H NMR (D2O): o = 0.73 ppm (s, 3H, cholate CH3); 0.96 (br. m, 6H, cholate CH3); 0.99 (d, J= 6.0Hz, 3H, CH3CH); 1.0-2.4 (m, aliphat. cholate CH); 1.3-1.8 (br. m, 2H, CHNH-CH2); 2.94-3.16 (br. m,1H, CHNH-CH2); 3.38 (s, 3H, CH30); 3.4-3.9 (O-CH2, N-CH2, O-CH); 3.91 (br. s,1 H, CHOH); 4.08 (br. s, 20 1 H, CHOH).
~ CA 02263671 1999-02-18 Example 4:
5NH2 NH2 NH m: n= 0.95: 0.05 XHa XHa nH (~ H
~/ / OCH3 <)~~~ / O~H3 Tso'~O~OH
100 mg of polyvinylamine were dissolved in a mixture of 20 ml of water and 20 ml of ethanol. pH = 10 was set. 350 mg (20 mol%) of Example 3e were added in portions at 40-50~C. The solution was stirred at room temp. for 4 h and then heated under reflux for 3 h. After allowing to stand for a further 3 days, Example 3e was still detectable. The mixture was adjusted to pH = 12 and then heated under reflux for a further 7 h. After cooling, the polymer product was isolated by ultrafiltration (5000A membrane; ethanol/
water = 1 :1) and subsequent freeze-drying. Yield: 170 mg of Example 3f.
The 1H NMR analysis showed a degree of substitution of about n = 5%.
1H NMR: (D2O) d = 0.73 ppm (s, 3H, cholate CH3); 0.96 (br. m, 6H, cholate CH3); 0.99 (d, J= 6.0Hz, 3H, CH3CH); 1.0-2.4 (m, aliphat. cholate CH); 1.3-1.8 (br. m, 2H, CHNH-CH2); 2.94-3.16 (br. m,1H, CHNH-CH2); 3.38 (s, 3H, CH30); 3.5-3.85 (O-CH2, N-CH2, O-CH); 3.89 (br. s,1 H, CHOH); 4.05 (br.
s,1 H, CHOH).
- Example 5:
+
O NH O NH o Cl~
o~OH
I
= / m: n= 0.57: 0.43 ~ rr-- ~--n O NH O NH 1~l ~~'~0 Na lCI-o~OH
132 mg of 3-methacryloylamidopropyltrimethylammonium chloride were added to a solution of 344 mg of comonomer I (synthesis as described in Pat. EP 548793) in 2 ml of ethanol. Nitrogen was passed into the mixture for 45 min. 662 ,ug of Trigonox 62 (t-butylperoxydiethyl acetate; AKZO
Chemicals) or dibenzoyl peroxide were then added under a nitrogen atmosphere. The mixture was stirred at 75~C for 27 h with exclusion of air.
As starting material was still detectable, 687 ,ug of VA-044 (2,2 -azobis-[2-(2 -cyanovaleric acid)]; 75% strength solution in water; Wako Chemicals) were added under a nitrogen atmosphere. The mixture was stirred at 45-50~C for 20 h. 5 ml of 20% strength aq. sodium hydroxide solution were then added and the mixture was stirred at 45~C for 18 h.
150 ml of water were then added. pH = 7 was set by addition of dilute hydrochloric acid. Example 5 was then isolated by ultrafiltration (5000A
~ CA 02263671 1999-02-18 - membrane; methanol/water = 1 :2).
1H NMR: (D2O) o= 0.73 ppm (s, 3H, cholate CH3); 0.96 (br. m, 6H, cholate CH3); 0.99 (d, J= 6.0Hz, 3H, CH3CH); 1.0-2.4 (m, aliphat. cholate CH); 1.3-1.8 (br. m, 2H, CHNH-CH2); 2.94-3.16 (br. m,1H, CHNH-CH2); 3.38 (s, 3H, CH30); 3.5-3.85 (O-CH2, N-CH2, O-CH); 3.89 (br. s, 1 H, CHOH); 4.05 (br.
s,1 H, CHOH).
Ratio: 57:43 Example 6:
OH ~ ~ OH
NH2 NH +
(CH2),2 ~ >
--IN--_ OH
~ ~OH
NH2NH NH I >
(CH2) 12 ~' --N-- OH
I Cl l: m: n = 0.84: 0.15: 0.01 600 mg of trimethylammoniumdodecyl-substituted polyvinylamine (degree 30 of substitution 20%) were dissolved in a mixture of 10 ml of water and 10 ml of methanol. The mixture was warmed to 45-50~C. 239 mg (10 mol%) of 3-mesylcholic acid (Example 1 a) were then added, the pH
being kept at 8-10 by addition of dilute sodium hydroxide solution. The clear solution was stirred at 45-50~C for 15 h. The product was purified by . . , ultrafiltration (5000A membrane) in methanol/water = 1 :1 and isolated by freeze-drying. Yield: 550 mg.
1H NMR: (D2O) o = 0.8-2.2 (m), 2.25-4.2 (m), 3.04 (s, N-CH3). Degree of substitution as indicated above.
Example 7:
Example 7a:
O O
~OH ; 1~OH
+ Br-(CH2)6~r ~ ,~
HO OH Br--(CH2)6--O OH
12.3 9 (30 mmol) of cholic acid were dissolved in 200 ml of THF. 73.2 9 (300 mmol) of 1,6-dibromohexane were then added and the mixture was heated under reflux.10.2 9 (180 mmol) of potassium hydroxide powder were then added in portions in the course of 6 h. The mixture was then stirred for a further 1 h. After cooling, the resulting precipitate was filteredoff with suction and washed with THF. The filtrate was concentrated.
Excess dibromohexane was distilled off in vacuo. The viscous residue was purified by column chromatography (ethyl acetate -> ethyl acetate:methanol = 9:1). Yield: 6 9 1H NMR: (CDCI3) ~ = 0.68 ppm (s, 3H, cholate CH3); 0.89 (br. m, 6H, cholate CH3); 0.99 (d, J= 6.0Hz, 3H, CH3CH); 1.0-2.4 (m, aliphat. cholate CH); 1.3-1.8 (br. m, 2H, CHNH-CH2); 2.6-2.9 (br. m, 3H); 3.42 (d, J= 6.0Hz, 2H); 3.84 (br. s,1 H, CHOH); 3.96 (br. s,1 H, CHOH); 4.06 (d, J= 6.0Hz, 2H).
MS: Cl (ammonia): m/e[%]= 590 (M+NH4 of 31Br isotope, 95); 588 (M+NH4 - von 79Br isotope, 100).
Example 7b:
O
~ OH I OH
NH2 1 >
X HCI ~
Br--(CH2)6--O~OH O
OH ~OH
NH2 NH--(CH2)6--~ OH
x HCI
m: n= 0.98: 0.02 10 9 of polyallylamine hydrochloride were dissolved in 100 ml of water and the pH was adjusted to pH = 10 using dil. sodium hydroxide solution. 3.1 9 of Example 7a were added at 50-60~C in the course of 3 h, a temporary cloudiness occurring each time. The pH was kept at pH = 9.5-10 by addition of dil. sodium hydroxide solution. The mixture was stirred at 60~C
for 4 h. The product was purified by ultrafiltration in methanol/water = 1:1 and subsequent freeze-drying. Yield: 7.4 9.
1H NMR: (D2O) o = 0.72 (br. s, 3H, cholate CH3), 0.92 (br. s, 3H, cholate CH3), 0.95-2.2 (m, aliphat. CH), 2.72 (br. s, 2H, CH2-NH2), 2.9-4.2 (m, CHOH, CH2O inter alia). Degree of substitution of cholate: 2%.
. CA 02263671 1999-02-18 Example 8:
OH \~OH
~NH N~
Meso~ O OH O
~ OH
~/
MesO l l ~ NH I ~ o~~OH
O
233 mg (0.44 mmol) of 3-(2-mesyl)ethoxycholic acid were dissolved in 1 ml of methanol and 75 mg (0.44 mmol) of 3-(N,N-dimethylaminopropyl)-methacrylamide were then added. After 20 min, a precipitate resulted. The mixture was stirred at 50~C for 14 days. The solvent was stripped off and the residue was chromatographed 3 times on silica gel (methanol ->
methanol/water/acetic acid = 10:0.5:0.05). 50 mg of product were obtained.
1H NMR: (CD30D) ~ = 0.71 (s, 3H, cholate CH3), 0.94 (s, 3H, cholate CH3),1.01 (d, J= 7 Hz, 3H, cholate CH3CH),1.0-2.5 (m, aliphat. CH), 2.80 (s, 3H, mesylate anion), 3.0-4.0 (several m, CHOH, CH2O inter alia), 3.16 (s, 6H, N-CH3), 5.40 (br. s, 1 H, vinyl-H), 5.74 (br. s, 1 H, vinyl-H).
MS: m/e[%]= 605 (M+).
- Example 9:
Example 9a:
o OH \~OH
NH~N~ + ~/
Br--(CH2)6--O~OH
OH
,~,J
O N--(CH2)6--O~OH
251 mg (0.44 mmol) of 3-(6-bromohexyloxy)cholate were dissolved in 2 ml of methanol and 75 mg (0.44 mmol) of 3-(N,N-dimethylaminopropyl)-methacrylamide were then added. The mixture was heated under reflux for 6 h and then allowed to stand overnight. The solvent was stripped off and the residue was chromatographed on silica gel (methanol -> methanol/
water/acetic acid = 99:0.5:0.5).160 mg of crude product were obtained, which was further purified by means of a weakly acidic ion exchanger.
Yield: 80 mg.
1H NMR: (CDCI3) o= 0.67 (s, 3H, cholate CH3), 0.87 (s, 3H, cholate CH3), 0.99 (d, J= 7 Hz, 3H, cholate CH3CH), 1.0-2.4 (m, aliphat. CH), 3.1-4.1 (several m, CHOH, CH2O inter alia), 3.15 (s, 6H, N-CH3), 3.86 (s), 5.35 (br. s,1 H, vinyl-H), 5.85 (br. s,1 H, vinyl-H).
~ CA 02263671 1999-02-18 Example 9b:
o d~NH~ I + + ~OH
O I ) /\~\
~ (CH2)6--~ ./ OH
~ m:n= 0.70:0.30 n O
O NH O NH OH ~O Na (CH2)6--O~
0.52 mg of free radical initiator VA 044 (Wako) was added to a solution of 55 mg (77 I~mol) of Example 9a and 17 mg (77 ,umol) of trimethyl-20 ammoniumpropyl methacrylate chloride in 3 ml of water. The mixture was deaerated and then stirred at 45~C for 70 h. The mixture was evaporated and the residue was dissolved in 10 ml of water and purified by ultrafiltration (5000A membrane). After freeze-drying, 66 mg of Example 9b were obtained.
1H NMR: (CDCI3) ~i = 0.67 (s, 3H, cholate CH3), 0.87 (s, 3H, cholate CH3), 0.99 (d, J= 7 Hz, 3H, cholate CH3CH),1.0-2.4 (m, aiiphat. CH), 3.1-4.1 (several m, CHOH, CH2O inter alia), 3.15 (s, 6H, N-CH3), 3.86 (s), 5.35 (br.
s,1 H, vinyl H), 5.85 (br. s,1 H, vinyl H).
. CA 02263671 1999-02-18 Example 9c:
OH ~OH
~~\
~NH----N--(CH2)6--O~OH
-- ~--n O
O NH OH~O Na ~ Cl J ' (CH2)6--o OH
Nitrogen was passed through a solution of 741 mg (1.0 mmol) of Example 9a in 3.5 ml of methanol for 30 min. The solution was then warmed to 60~C. 10 mg of free radical initiator VA 044 (Wako) were added. The mixture was then stirred at 60~C under a nitrogen atmosphere for 4 h. It was then diluted with water and purified by ultrafiltration (5000 A
membrane). For the exchange of the counterion Br~ - Cl- it was then washed twice with dilute aqueous NaCI solution and then twice with water.
After freeze-drying, 456 mg were obtained.
Elemental analysis:
Calculated: C 66.4 % H 10.4 % N 14.3 % Cl 5.3 %
Found: C 66.2 % H 10.5 % N 14.2 % Cl 5.2 %
~ CA 02263671 1999-02-18 - Example 10:
+
ONH O NH o ~J\OCH3 ~N~
O~OH
m: n = 0.50: 0.50 ~,~--n~ n O NH O NH O
î~ X ' ~ Na x HCI
O~OH
38 mg (0.35 mmol) of N-(3-N,N-dimethylaminopropyl)methacrylamide and 200 mg (0.35 mmol) of comonomer I were dissolved in 1.39 ml of ethanol.
5 Nitrogen was passed into the mixture with stirring for 45 min. 0.66 mg of VA 044 initiator was then added. The mixture was stirred at 45-50~C for 27 h. After cooling, the resulting copolymer was isolated by ultrafiltration in water (5000A membrane) and subsequent freeze-drying. Yield: 196 mg.
.. . .. .. . ..
. CA 02263671 1999-02-18 Example 11:
~--~OCH3 NH2 ~ NH~
l m:n= 0.95 005 OH ~\~O Na _- - ~
~Hi'-- ~H
x HCI
181 mg (3.19 mmol) of allylamine were added at room temp. to a solution of 80 mg (0.17 mmol) of I in 3 ml of ethanol. Nitrogen was passed into the mixture for 1 h. 1.14 mg (1 mol%) of VA 044 initiator were then added. The mixture was stirred at 50~C for 15 h. The mixture was concentrated and the residue was stirred at 70~C for 4 h in 5 ml of 20% strength aq. sodium hydroxide solution. The solution was adjusted to pH = 7. The product was isolated by ultrafiltration in water (5000A membrane) and subsequent freeze-drying. Yield: 106 mg.
... .. . . .
.
- Example 12:
~ m:n= 0.8:0.2 NH2 NH + 1~l x HCI (CH2)10 OH\~OH
--N+ _ I Cl ~/
Br--(CH2)6--O~----'OH
~ ~ OH : I~OH
CH2 CH2 Cl H2 , ~, >
NH2 NH NH ~ T
(CH2) 10 (CH2)6 ~ OH
--N--I Cl-I: m: n = 0.79: 0.20: 0.01 1.74 9 of sodium hydroxide powder were added at room temp. to a solution of 5.00 9 (43 mmol) of I in 100 ml of water. A solution of 1.98 9 of ll in 60 ml of methanol was then added. The mixture was stirred at 60~C for 6 h.
The mixture was diluted to a volume of 21 with water. The pH was adjusted to pH = 7. The product was isolated by ultrafiltration in water (5000A
membrane) and subsequent freeze-drying.
Yield: 5.63 9.
1H NMR (D2O): I: m: n = 0.79: 0.20: 0.01 . CA 02263671 1999-02-18 - Example 13:
~ m: n= 0.8: 0.2 5 NH2 NH + ~
x Ha (CH2)l0 OH \r~ OH
--N+ ~
Cl~
10Br--(CH2)6--O'~ 'OH
OH ~OH
(CHz)lo (CH2)6 ~ OH
I Cl-I: m: n =0.79: 0.20: 0.01 2.22 9 (55.6 mmol) of sodium hydroxide powder were added at room temp.
to a solution of 5.00 9 (55.6 mmol) of I in 100 ml of water. A solution of 2.54 9 of ll in 75 ml of methanol was then added. The mixture was stirred 25 at 60~C for 8 h. The mixture was diluted to a volume of 2 I with water. The pH was adjusted to pH = 7. The product was isolated by ultrafiltration in water (5000A membrane) and subsequent freeze-drying.
Yield: 5.50 9.
1H NMR (D2O): I: m: n = 0.79: 0.20: 0.01 - Example 14:
o ,~OCH3 ~" + ~, xNHHcl ~ NHJ--J'OH
_ _ _ I
~;~ ~ ~ O Na x HCI <> ~~
O NH~OH
m: n = 0.99: 0.01 274 mg (0.50 mmol) of I were added at room temp. to a solution of 107 mg (2.5 mmol) of polyvinylamine in 5 ml of ethanol. The pH of the solution was adjusted to pH = 9-10 and the mixture was stirred at room temp. for 1 week. The mixture was concentrated to a quarter of the volume and treated with 10 ml of 10% strength aqueous sodium hydroxide solution. It was stirred at room temp. for 2 days and the pH was then adjusted to pH = 7.
The product was isolated by ultrafiltration in water (5000A membrane) and subsequent freeze-drying.
Yield: 90 mg.
1H NMR (D2O): m: n = 0.99: 0.01 - Example 15:
Example 15a:
O O
~X ~OH ~OH
~~ + Br-(CH2)~0-Br HO~OH Br--(CH2)l0 O~OH
4.1 g (10 mmol) of cholic acid were dissolved in 100 ml of THF. 9.0 g (30 mmol) of 1,10-dibromodecane were then added and the mixture was 15 heated under reflux. 3.4 g (60 mmol) of potassium hydroxide powder were then added in portions in the course of 5 h. The mixture was then stirred for a further 1 h. After cooling, the resulting precipitate was filtered off with suction and washed with THF. The filtrate was concentrated. Excess dibromodecane was distilled off in vacuo. The viscous residue was purified 20 by column chromatography (ethyl acetate). Yield: 0.81 g . CA 02263671 1999-02-18 Example 15b:
+ ~OH
NH2 1 >
XHa ~
Br--(CH2),0 O~OH O
OH ~OH
NH2 NH--(CH2),0 O OH
x HCI
m: n = 0.99: 0.01 1.5 g of polyallylamine hydrochloride were dissolved in 15 ml of water and 10 ml of methanol and the pH was adjusted to pH = 10 using dil. sodium hydroxide solution. 0.5 g (5 mol%) of Example 1 5a were added at 50-60~C
in the course of 2 h, a temporary cloudiness occurring. The pH was kept at pH = 9.5-10 by addition of dil. sodium hydroxide solution. The mixture was stirred at 60~C for 5 h. The product was purified by ultrafiltration (3000A
membrane) in ethanol/water = 1:1 and then in water and subsequent freeze-drying. Yield: 0.95 g.
1H NMR: (D2O) degree of substitution of cholate: 1%.
. CA 02263671 1999-02-18 - Example 16:
OH ''f--I~OCH3 ~N O O~X/
l O
OH \~O Na _- -O
x HCI m: n = 0.97: 0.03 Nitrogen was passed for 30 min through a solution of 63 mg (0.14 mmol) of methyl 3-acryloylcholate in 2 ml of ethanol. 250 mg (2.60 mmol) of N-vinylimidazole (Polyscience) and 8.9 mg (0.027 mmol) of VA 044 initiator were then added. The mixture was warmed to 45-48~C under nitrogen and stirred at this temperature for 2 days. A viscous material was obtained.
This was dissolved in 10 ml of methanol. 3 ml of 20% strength aqueous sodium hydroxide solution were then added and the mixture was stirred at 50~C for 12 h. The pH was adjusted to pH = 7. The product was isolated by ultrafiltration (5000A membrane) in water and subsequent freeze-drying.
Yield: 200 mg.
1H NMR: (D2O) degree of substitution of cholate: 3%.
. CA 02263671 1999-02-18 Example 17:
OH \~\/ OH
S ,~ +
MesO OH
l O
~k ~OH
X HCI --/
~1~ OH
m: n= 0.99: 0.01 500 mg of polyvinylamine were dissolved in a mixture of 10 ml of water and 10 ml of ethanol. 57 mg of 3-mesylcholic acid were added in portions at 40-50~C. The pH was kept between 9 and 10. The mixture was stirred at 40-50~C for 9 h. 200 ml of ethanol:water = 1 :1 were then added. The product was isolated by ultrafiltration (5000A membrane) in water and subsequent freeze-drying.
Yield: 500 mg.
1H NMR: (D2O) degree of substitution of cholate: 1%.
, - Example 18:
+
O NH O NH o O~OH
m: n= 0.50: 0.50 --rr-- ~--n O NH O NH O
~ ~ ~ O Na x HCI
O--/~OH
139 mg (0.63 mmol) of 3-methacrylamidopropyltrimethylammonium chloride and 4.1 mg (0.013 mmol) of VA 044 initiator were added to a deaerated solution of 300 mg (0.63 mmol) of methyl 3-acryloylcholate in 2.1 ml of ethanol. The mixture was stirred at 45-48~C for 2 days under nitrogen. Monomers were no longer detectable on TLC checking. The pH
was adjusted to pH = 7 and 50 ml of water were added. The product was isolated by ultrafiltration (5000A membrane) in water and subsequent freeze-drying. Yield: 370 mg.10 ml of THF and 1 ml of 20% strength sodium hydroxide solution were added to this product. The mixture was warmed at 50~C. Since a homogeneous solution was not obtained, the THF was distilled off in vacuo.100 ml of water were added and the mixture was stirred at room temp. ovemight. The pH was adjusted to pH = 7.
Example 18 was then isolated by ultrafiltration (5000A membrane;
- methanol/water = 1 :1 ) and subsequent freeze-drying.
1H NMR: (D2O): ratio:70:30.
In the bovine bile assay adsorption test, the ability of the polymer to adsorb bile acids is measured.
Bovine bile assay adsorption test:
The samples were prepared as follows:
An aqueous solution is first prepared which contains the following salts in the concentrations indicated below:
NaCI 90 mmol/l KCI 6 mmol/l CaCI2 3 mmol/l NaHCO3 10 mmol/l Sodium taurocholate1.38 g/l Sodium glycocholate2.49 g/l The pH of the solution is adjusted to pH = 7.0 + 0.2.
25 10 ml of the above solution are taken and added to a sample vessel.
20 mg of the polymer (Examples 1 to 18) are then added. The mixture is slowly stirred for 2 h and then centrifuged (5000 rpm). A sample of 30 ,ul is taken from the supernatant for analysis and analyzed as described in the following.
- HPLC with FLUORESCENCE DETECTiON
Equipment: HPLC unit from Kontron, consisting of three pumps and mixing chamber, autosampler, UV detector and analysis unit with MT2 software.
Fluorescence detector from Merck-Hitachi As the samples are light- and temperature-sensitive, the autosampler is cooled to about 5~C.
Mobile phase: Eluent A: ~'Millipore water (own unit) Eluent B: acetonitrile/methanol 60:30 Column: ~'LiChrospher 100 RP-18, 25 mm, 5 ,um from Merck Precolumn: LiChrospher 60 RP-select B, 4 mm, 5,um from Merck Flow rate: 1.3 ml/min Detection: Excitation: 340 nm Emission: 410 nm Gradient: 0.00 min 66 % B
7.50 min 66 % B
The object is achieved by binding bile acid molecules or low molecular 10 weight bile acid absorption inhibitor molecules firmly to a polymer molecule covalently or via a spacer group, such that they are no longer absorbable themselves, but their absorption-inhibiting action is still retained. In this way, the systemic cytotoxic side effects of the low molecular weight absorption inhibitors which occur in some cases and can be caused by 15 their absorption, are avoided. The polymer, for its part, is too large to be absorbed. The polymer additionally contains bile acid adsorber centers, e.g. quaternized nitrogen centers, in the molecule. These reduce the bile acid concentration in the intestine, which is increased by the receptor blockade, by binding and adsorbing bile acid anions.
20 Polymers of this type thus have a dual action. On the one hand, they act as polymeric bile acid absorption inhibitors due to the covalently firmly bonded receptor blocker units and, on the other hand, as bile acid adsorbers.
The invention therefore relates to vinyl copolymers consisting of units of 25 the formula I
~CH2 C3~CCH2--C3~ECH2--c3 L oR4 ~ B
~\1 1 ~~oR5 and their physiologically tolerable salts, in which:
R1, R2, R3 are hydrogen or CH3;
R4, R5 are hydrogen, (C1-C6)-alkyl, (C1-C6)-acyl;
d is 0.01 to 1.00;
e is 0 to 0.99;
f is 0 to 0.99;
where d + e + f must be equal to 1;
L is a bond, -NH-, -N(CH3)-, -+NH2CI--, -+NH(CH3)CI--, -+N(CH3)2CI--, NH-CO-, -NH-(CH2)n-, ~NH-[(cH2)n-o-]m-(cH2)p-~ ~NH~(CH2)n~
-NH-co-(cH2)p-~-NH-(cH2)n-co-NH(cH2)m-N-(cH3)2 Cl~(CH2)m~~
-NH-[CH2-CH(CH3)-O-]m-CH2-CH(CH3)-, -NH-(cH2)m-N(cH3)2 Cl~(CH2)n~~
-O-(CH2)n-, ~~~(CH2)n~C~~~
-CO-, -CO-NH-, -CO-N(CH3)-, -CO-NH-CO-, -CO-NH-(CH2)n-, -CO-NH-[(CH2)n-O-]m-(CH2)p-, -CO-NH-(CH2)n-CO-, -CO-NH-CO-(CH2)n -, -co-NH-[cH2-cH(cH3)-o-]m- CH2-CH(CH3)-' -CO-NH-(CH2)m-+N(CH3)2CI ~(CHZ)n~~
-CO-(CH2)n-O-(CH2)p-CO-, -Ar-, -Ar-CO-, -Ar-CH2-, -Ar-CH2-+N(CH3)2CI ~(CH2)n~~ -CO-Ar-CO-, -(C1 -C1 2)-alkylene-, I
-NH-CH2-Ar-CH2-N ~(CH2)n~~
I
CH3 Cl -NH-Ar-CO-, -NH-CH2-Ar-CH2-, -NH-CO-Ar-CO-;
H is a bond, -CH2-, -Ar-, -Ar-CH2-, where Ar is phenylene, naphthylene;
m is 1 to 18;
n is 1 to 18;
p is 1 to 18;
A is -O-, -NH-, a bond;
B js-oH~-oNal-oK7-NH2~-NH-cH3~-N(cH3)2~-NH-cH2-cH2-SO3Na, -NH-CH2-COONa, -NH-CH2-CH2-+N(CH3)3CI-, -~-(C1 -C18)-alkyl~-NH-(c1-c6)-alkyl~ NH-(C1-C6)-alkYIene-HO
~ ~ ~R7 ~A3H OH
R7 is-OH,-O-(C1-C6)-alkYl~-NH2;
Y is -NH2, -+NH3CI--, -NH-R9, -+NH2R9 Cl--, -NR9R10, -+NR9R10R11 Cl~,-(C1-C18)-alkylene-NH2-,-(C1-C18)-alkylene-+NH3CI~-,-(C1-C18)-alkylene-NHR9, -(C1-C18)-alkylene-NR9R1~, -(C1-C18)-alkylene-+NR9R10R1 1CI-, -NH-CO-(C1-C18)-alkyl, -NH-CO-(C1-C12)-alkylene-N R9R1 ~, -N H-CO-(C1 -C1 2)-alkylene-+N R9R1 0R11 Cl-, -COR9, -CO-, CO NH-(C1-C18)-alkylene-+NR9R1~R11CI~ ph , -phenylene-(CO-C6)- alkylene-NH2, -phenylene-(CO-C6)-alkylene-NH-R9, -phenylene-(C0-C6)-alkylene-NR9R1 ~, -phenylene-(C0-C6)-alkylene- +NR9R10R11CI-, -CO-NH-R9, -NH-(C1-C18)-alkylene-NHR9, -NH-(C1 -C18)-alkylene-NR9R1~, -NH-(C1 -C18)-alkylene-+NR9R10R1 1 Cl-, -COOH, -O-R9, -CONH2, -O-CO-R9, -CO-(Cl-Cl2)-alkyl, -O-CO-(Cl-Cl2)-alkylene-NR9Rl~, -O-CO-(Cl-C12)-alkylene-+NR9R10Rll Cl-, N~N +) F ~ --N/~ ~ --N~3 Cl N~ Cl- , - C - O - C H 2 - C H - C H 2-~ H
-~-NH-(CH2)m-NR9R1 ~
-c-o-(c1-c18)-alkylene-+N-(c1-c18-alkyl)3 Cl-1~ 9 10 -C-O-(C1-C18)-alkylene-NR R
Z is -NH2, -+NH3CI--, -NH-R9, -+NH2R9 Cl--, -NR9R10, -+NR9R10R11 Cl-, -(C1-C18)-alkylene-NH2-, -(C1-C18)-alkylene-+NH3CI -, -(C1-C1g)-alkylene-NHR9,-(C1-C18)-alkylene-NR9R1~,-(C1-C18)-alkylene-+NR9Rl0Rl lCI-, -NH-CO-(Cl -Cl8)-alkyl, -NH-CO-(Cl-Cl2)-alkylene-.
NR9R1~, -NH-CO-(C1-C12)-alkylene-+NR9R1~R1 1CI~, -COR9, -CO-OR9, -CO-NH-(C1-C18)-alkylene-+NR9R1~R1 1CI-, -phenyl, -p h e nyle n e-(C O-C 6)-alkyle n e-N H 2, -p h e nyle n e-(C O-C 6)-alkyle n e-N H-R9, -phenylene-(C0-C6)-alkylene-N R9R1 ~, -phenylene-(C0-C6)-alkylene- +NR9R10R11CI-, -CO-NH-(C1-C12)-alkyl, -NH-(C1-C18)-alkylene-NHR9, -NH-(C1-C18)-alkylene-NR9R1~, -NH-(C1-C18)-alkylene-+NR9R1~R11 Cl-,-COOH, -O-R9, -CONH2, -O-CO-R9, -CO-(C1 -C12)-alkyl, -O-CO-(C1 -C12)-alkylene-NR9R1~, -O-CO-(C1 -C12)-alkylene-+NR9R10R11 Cl---N/~ Cl- /~ + fi~ Cl-\~N(+) ~ --N ' --N~
N~ Cl- , -C -O -C H 2-l H -C H 2-~ H
O
-~-NH-(CH2)m-NR9R1 ~
-C-O-(C,-C,8)-alkylene-N+-(C1-C,8-alkyl)3 Cl, or a crosslinker selected from the group consisting of:
-C~X-(C2-C6)-alkylene-X-CC CR1-CH2-' CA 02263671 1999-02-18 . ~
-(~-(C1 ~c3)~alkYlene)1 -1 8-0-CH-CH2 , -NH-(C1 -C1 2)-alkylene-NH-CH-CH2--NH-cH2-cH(oH)-cH2-NH-TH-cH2-, -NH-CHOH-(C,-C12)-alkylene- CHOH-NH-CH-CH2-X is 0, -NH-;
R9, R10 are (C1-C18)-alkyl-, -phenyl, -CH2-phenyl;
R1 1 is H, (C1 -C1 8)-alkyl-, -phenyl, -CH2-Phenyl;
where at least one of the radicals L, Y and Z must contain an ammonium center.
20 Preferred compounds of the formula I and their physiologically tolerable salts are those in which:
R1, R2, R3 are hydrogen or CH3;
R4, R5 are hydrogen;
d is 0.01 to 1.00;
e isOtoO.99;
f isOtoO.99;
where d+e+f must be equal to 1;
30 L is-NH-,-NH-(C1-C18)-alkylene-, -NH-((C1 -C3)-alkylene-0-)1 -1 8-(C1 -C3)-alkylene-, -CO-NH-, -CO-NH-(C1 -C18)-alkylene-, , - CA 0226367l l999-02-l8 - a~3 a--CaNH-(C1 -C1 8)-alkYIene- ~-(C1 -Cl g)-alkylen~, CH
o Il -CO-, -NH-(C1 -C6)-alkylene-C-NH-;
H is a bond, -CH2-;
A is -O-, a bond, -NH-;
15 B is-OH,-ONa,-OCH3,-NH-CH2-CH2-OCH3, HO \,/~\~
~O~OH
~' ~A~N~J\OH
Y is-NH2,-NHR9,-NR9Rl~,-+NR9R1~R1lCI~,-NH-(C1-C18)-alkylene-+NR9Rl0RllCI-,-CH2-NH2,-CH2-NH-R9,-CH2-NH-(Cl-Cl8)-alkylene-NR9R1~,-CH2-NH-(C1-C18)-alkylene-+NR9R1~R11CI~,-NH-CO-R9, -CO-NH-R9, -CO-NH-propylene-+NR9R10R1 1CI-, ~ +
\~ N
N~
-CO-O-(Cl-Cl8)-alkylene-NR9R1~;
- Z is-NH2,-NHR9,-NR9R1~,-NH-(C1-C18)-alkylene-+N-(CH3)3CI~, -CH2-NH2, -CH2-NH-R9, -CH2-NR9R1~, -CH2-NH-(C1 -C18)-alkylene-+NR9R10R11CI-, or a crosslinker selected from the group consisting of:
-NH(C1 -C1 2)-alkylene-NH-CH-CH2--CO-X-(C2-C18)-alkylene-X-C~CR1-CH2--NH-CH2-CH(OH)-CH2-NH-CH-CH2-;
I
X is-O-,-NH-;
R9, R10, R11 are (C1-C6)-alkyl-, -phenyl, -CH2-phenyl, 15 where at least one of the radicals L, Y and Z must contain an ammonium center.
Particularly preferred compounds of the formula I and their physiologically tolerable salts are those in which:
R1, R2, R3 are hydrogen;
R4, R5 are hydrogen;
d is 0.01 to 1.00;
e isOtoO.99;
f is O to 0.99;
where d+e+f must be equal to 1;
L is-NH-cH2-cH2-o-cH2-cH2-o-cH2-cH2 o -C-NH-(C1 -C1 8)-alkylene-, -NH-(C1 -C1 8)-alkylene-, -CO-, -NH-, .
CA 0226367l l999-02-l8 -C-NH-(C1 -C6)alkYIene-~ -(C1 -C1 8)-alkYIene -(C1 -C6)-alkylene-NH-(C~ -C6)-alkylene-;
H is a bond, -CH2-;
A is -O-, -NH-, a bond;
B is-OH,-ONa,-NH-CH2-CH2-OCH3;
Y is-NH2,-NHR9,-NH-(C1-C18)-alkylene-+N(CH3)3CI~,-CO-NH-(C1-C10)-alkylene-+N(CH3)3CI~, -CO-NH-(C1 -C6)-alkylene-N(CH3), -CH2-NH2,-CH2-NHR9;
Z is-NH2,-NHR9,-CH2-NH2,-CH2NHR9,-NH-(C1-C18)-alkylene-+N-(CH3)3CI~,-CH2-NH-(C1-C18)-alkylene-+N-(CH3)3CI~,-CO-NH-propylene-+N(CH3)3CI~;
where at least one of the radicals L, Y and Z must contain an ammonium center.
25 Physiologically tolerable acid addition salts is understood as meaning readily water-soluble, soluble or sparingly soluble compounds according to the definition in the "German Pharmacopeia" (9th Edition 1986, official edition, Deutscher Apotheker-Verlag Stuttgart), page 19. The hydrochlorides and sulfates of the compounds are preferred.
An ammonium center is understood as meaning a positively charged nitrogen atom (quaternized).
The invention furthermore relates to a process for the preparation of the ' CA 02263671 1999-02-18 . _ .
- polymers consisting of units of the formula 1.
General description of the preparation process of the polymers:
5 The synthesis of the cholate-containing monomers was carried out as described in the examples.
Method 1:
Bonding of a linker to cholic acid and subsequent polymer-analogous 10 reaction with a polymer containing amino groups Cholic acid is first mesylated with methanesulfonyl chloride in basic medium. The mesyl group is a good leaving group and makes possible the addition of side chains, e.g. of a triethylene glycol unit, by nucleophilic 15 substitution. The free hydroxyl group of the triethylene glycol unit is then selectively activated by reaction with tosyl chloride. The tosyl leaving group thus formed makes possible the polymer-analogous reaction with polymers containing amino groups, e.g. polyallylamine or polyvinylamine (Example 1 d). The degree of substitution can be adjusted by changing the 20 polyamine: cholic acid derivative ratio.
Method 2:
Preparation of cholic acid amido ethers and subsequent bonding of a linker and polymer-analogous reaction with polymers containing amino groups Cholic acid is first converted into the active ester using p-nitrophenol. The amido ether is then obtained by reaction with 2-methoxyethylamine (Example 3b). This is linked via a linker to a polymer containing amino groups as described in Method 1.
Method 3:
Free radical copolymerization of acrylic-substituted cholic acid derivatives with vinylic monomers CA 0226367l l999-02-l8 - An acrylic-substituted cholic acid derivative is reacted with a vinylic (preferably acrylic) monomer by free radical copolymerization (see Example 5). Ester groups which may possibly still be present in the cholate radical can be selectively hydrolyzed under basic conditions.
Method 4:
Polymer-analogous reaction of mesyl-substituted cholic acid with polymers containing amino groups Cholic acid mesylate can be directly reacted with polymers containing amino groups, e.g. polyamines, in a polymer-analogous reaction at pH = 8-10. Substituted polyamines can also be employed here (Examples 6, 17).
Method 5 Introduction of a linker group by reaction of cholic acid with dibromoalkanes and subsequent polymer-analogous reaction with polymers containing amino groups In this method, a direct reaction of cholic acids with a dibromoalkane, e.g.
dibromohexane, is achieved in THF in basic medium (Examples 7a, 15). A
large excess of dibromoalkane is important here. The omega-bromoalkoxy cholic acid obtained is then converted into the polymer according to the invention in a polymer-analogous reaction with a polymer containing amino groups, e.g. a polyamine (Examples 7b, 12, 13, 15).
Method 6 Synthesis of a cholic acid derivative with a cationic center in the linker group and subsequent homo- or copolymerization of the monomer 30 obtained 3-(N,N-Dimethylaminopropyl)methacrylamide is reacted with a bromo- or mesyl-substituted cholic acid derivative in a Menschutkin reaction. The 3-amino group is quaternized here and a highly water-soluble acrylate-- substituted cholic acid derivative is produced (Examples 8, 9a). This can be homopolymerized under free radical conditions or copolymerized with other vinylic comonomers (Example 9).
5 Method 7 Free radical copolymerization of acrylic-substituted cholic acid with allylamine (hydrochloride) or another vinylic polymerizable amine Allylamine (hydrochloride) and other vinylic amines which can be 10 polymerized under free radical conditions can be directly polymerized with acrylic-substituted cholic acid derivatives (Examples 11, 16).
Method 8 Polymer-analogous Michael addition of acrylic-substituted cholate to 15 polymers containing amino groups In this reaction, an acrylic-substituted cholic acid derivative is reacted with a polymer containing amino groups, e.g. a polyamine, in alcoholic solution at pH = 9-10 in a Michael addition.
The present invention also relates to pharmaceutical preparations which comprise one or more of the active compounds according to the invention and, if appropriate, further hypolipidemic agents.
25 The active compounds according to the invention are suitable for use as hypolipidemic medicaments.
The active compounds according to the invention are used, for example, as pharmaceutical preparations, foodstuffs additives, formulation 30 auxiliaries, detergents, medicaments for influencing the enterohepatic circulation of the bile acids, medicaments for influencing lipid absorption, medicaments for influencing the serum cholesterol level, medicaments for the concentration-dependent inhibition of bile acid absorption in the gastrointestinal tract or as medicaments for the prevention of ' CA 02263671 1999-02-18 - arteriosclerotic symptoms.
Experimental section:
Example 1:
a) Example 1a: Cholic acid mesylate:
O O
,~OH ,~, J OH
~ ~l ~
O
1a 9.2 ml (117 mmol) of methanesulfonyl chloride were added dropwise at 0~C to 40.9 g (100 mmol) of cholic acid in 200 ml of pyridine in the course of 20 min. The mixture was first stirred at 0~C for 15 min and then at room temperature for 5 h. After standing overnight, the mixture was poured onto 1000 ml of ice water/200 ml of conc. sulfuric acid and stirred for a further 10 min. The resulting precipitate was filtered off with suction and washed with water. The precipitate was then dissolved in methylene chloride and the solution was extracted with water. The organic phase was dried using sodium sulfate and evaporated. The product (Example 1 a) was obtained quantitatively and employed for the subsequent step without further purification.
1H NMR: (CDCI3) o = 0.69 ppm (s, 3H, CH3); 0.91 (s, 3H, CH3); 0.99 (d, J=6.0 Hz, CH3CH), 0.9-2.6 (m, 24 H, aliphat. CH), 2.99 (s, 3H, CH3SO3); 3.87 (br. s, 1 H, CHOH); 4.01 (br. s, 1 H, CHOH); 4.50 (m; 1 H, CHOS02) ' CA 02263671 1999-02-18 Example 1b:
Adduct of triethylene glycol to cholic acid:
OH ,~OH
~~ ~X~ ~HO ~
H3C-S-O OH ~O ~ ~OH
la lb 6.1 9 (12.5 mmol) of Example 1a were suspended in 25 ml (150 mmol) of triethylene glycol and dissolved by briefly heating to 100~C. 4.0 9 (100 mmol) of magnesium oxide were added and the mixture was stirred at 100~C for 5 h. After standing overnight,100 ml of methylene chloride were added and the resulting precipitate was filtered off with suction and washed with methylene chloride. The organic phase was extracted with 200 ml of 2N aq. hydrochloric acid and then concentrated. Crude yield: 7.2 9. The crude material was purified by chromatography on silica gel (gradient ethyl acetate ~ ethyl acetate: methanol = 1: 1). The product fraction was precipitated with methylene chloride with stirring under ultrasound and the precipitate was filtered off. The filtrate contains pure Example 1 b. Yield after concentrating: 1.7 9 (25%) of Example 1 b.
1H NMR: (CDCI3) o = 0.69 ppm (s, 3H, CH3); 0.91 (s, 3H, CH3); 0.99 (d, J=6.0 Hz, CH3CH), 0.8-2.4 (m, 24 H, aliphat. CH); 3.5-3.75 (m,13H, O-CH2-CH2-O and CHR2OCH2); 3.85 (br. s,1 H, CHOH); 3.97 (br. s,1 H, CHOH) .
Example 1c:
~OH ~OH
~ ~ ~
~O~OH TsO~E o~ 'OH
1b 1c 248 mg (1.3 mmol) of tosyl chloride, dissolved in 20 ml of dichloromethane, were added in portions at 0~C in the course of 30 min to 600 mg (1.1 mmol) of Example 1b and 140 mg (2.5 mmol) of potassium hydroxide powder in 30 ml of dichloromethane. Since TLC checking still did not show complete reaction, a further 100 mg (1.8 mmol) of potassium hydroxide powder were added. The mixture was stirred at room temperature for a further 1 h. The resulting precipitate was filtered off. The filtrate was concentrated. Crude yield: 1.3 g. The crude product was dissolved in a little dichloromethane and purified by means of column chromatography on silica gel (ethyl acetate: methanol = 9: 1). Yield: 540 mg (70%).
1H NMR: (CDCI3) o = 0.68 ppm (s, 3H, CH3); 0.90 (s, 3H, CH3); 0.98 (d, J=6.0 Hz, CH3CH), 0.6-2.5 (m, 24 H, aliphat. CH); 2.44 (s, 3H, Ts-CH3);
3.5-3.75 (m,12H, O-CH2-CH2-O); 3.84 (br. s,1H, CHOH); 3.97 (br. s,1H, CHOH); 4.15 (m, 1H, CHR2OCH2); 7.34 (d, J=9Hz, 2H, aryl H), 7.79 (J=9Hz, 2H, aryl H).
~ , .
- CA 0226367l l999-02-l8 Example 1d:
2 I m:n=0.99:0.01 x HCI xHCI
;~ I 011 (~ 1~ 0 Na TsO~ OH
1c 1d 200 mg of polyvinylamine were dissolved in 20 ml of water and pH=10 was set. 66 mg (2 mol%) of 1 c, dissolved in 20 ml of ethanol, were added and pH=10 was again set. The mixture was stirred at 50~C for 6 h, the pH
changing to pH = 8. The pH was again adjusted to pH = 10 and the mixture 10 was allowed to stand ovemight at room temperature. The product 1 d was purified by ultrafiltration (membrane 5000A) using ethanol:water = 1:1 and isolated by freeze-drying of the retentate. Yield: 180 mg. 1 H NMR analysis showed a degree of substitution on the polyvinylamine of n = 1%.
1H NMR (D2O): o = 0.57 ppm (s, 3H, cholate CH3); 0.79 (br. m, 6H, cholate-CH3 and CH3CH); 1.0-1.6 (m, aliphat. cholate CH); 1.6-2.5 (m, CH2-CHNH and aliphat. cholate CH); 3.3-3.5 (O-CH2-CH2-O); 3.5-4.0 (br.
s, CHNH-CH2); 4.0-4.4 (m, CHOH and CHR2OCH2).
- Example 2:
NH2 NH2 NH m: n = 0.95: 0.05 xHa xHa + ~ ~o Na T90'E--o~/
1c 2 0.7 ml of 2N sodium hydroxide solution was added to a solution of 100 mg of polyvinylamine in 20 ml of ethanol and the mixture was warmed to 40-50~C. 496 mg of Example 1 c were added in portions in the course of 6 h.
10 The pH was kept at pH = 9 and the mixture was allowed to stand at room temp. for 3 days. The product 2 was purified by ultrafiltration (5000A
membrane) using ethanol:water = 1:1 and isolated by freeze-drying of the retentate. Yield: 170 mg, 1H NMR analysis showed a degree of substitution on the polyvinylamine of n = 5%.
1H NMR: as Example 1d.
- Example 3:
Example 3a:
O O
~J~OH ~ J1'O~3NO2 5 HO--/~OH HO--~OH
3a 20 g (49 mmol) of cholic acid were dissolved in 300 ml of THF and 10.2 g (73 mmol) of p-nitrophenol and a spatula tipful of p-N,N-dimethylamino-pyridine were added. The mixture was cooled to 0~C and 13.2 g (64 mmol) of dicyclohexylcarbodiimide, dissolved in 50 ml of THF, were then added.
The mixture was stirred at 0~C for 30 min and then at room temp. for 4 h, a precipitate forming. This was filtered off. The filtrate was concentrated to a half of the volume and treated with pentane until it began to get cloudy.
The mixture was stirred for a further 1 h and the resulting precipitate was filtered off. The combined precipitates were washed with toluene and dried.
Yield: 11.5 g. The combined filtrates were evaporated to dryness and the residue was dissolved in 100 ml of THF. The solution was again treated with pentane until it began to get cloudy and stirred for a further 1 h. The resulting precipitate was again filtered off. Yield: 4.5 g.
Total yield of Example 3a: 16.0 g (62%).
1H NMR: (CDCI3) o = 0.70 ppm (s, 3H, CH3); 0.90 (s, 3H, CH3); 1.06 (d, J=6.0 Hz, CH3CH), 0.9-2.8 (m, 24 H, aliphat. CH); 3.47 (br. s,1 H, CHOH); 3.85 (br. s,1 H, CHOH); 3.99 (br. s, 1 H, CHOH); 7.28 (d, J=9Hz, 2H, aryl H), 8.26 (d, J=9Hz, 2H, aryl H).
- Example 3b:
O O
~o~3No2 ~NH~oCH3 HO~OH HO--~OH
3a 3b 750 mg (10 mmol) of 2-methoxyethylamine were initially introduced into a mixture of 100 ml of ethanol and 100 ml of water and 5.9 g (11 mmol) of Example 3a were added in portions, the pH being kept at 10-11 by addition of sodium hydroxide solution. The cloudy mixture was stirred at 40-50~C for 4 h and then allowed to stand at room temp. for 3 days. The mixture was filtered and the filtrate was concentrated to a volume of 50 ml. By addition of hydrochloric acid, the pH was adjusted to pH = 1. The mixture was extracted twice with diethyl ether and then twice with dichloromethane. The ether extracts were discarded. The combined dichloromethane phases were evaporated after drying over sodium sulfate. Yield: 4.4 g (94%) of Example 3b.
1H NMR: (CDCI3) o = 0.68 ppm (s, 3H, CH3); 0.99 (s, 3H, CH3); 1.00 (d, J=6.0 Hz, CH3CH), 0.9-2.4 (m, 24 H, aliphat. CH); 3.36 (s, 3H, CH30);
3.45 (m, 5H, CHOH and NH-CH2-CH2-O); 3.84 (br. s,1 H, CHOH); 3.96 (br.
s,1 H, CHOH); 6.20 (br. s, 1 H, NH) .
~ Example 3c:
~ , ~ ~NH~oCH3 ~ ~ ~
HO OH H3C-S-O~OH
3b 3c 4.1 g (9.9 mmol) of Example 3b were dissolved in 20 ml of pyridine.
0.92 ml of methanesulfonyl chloride were added at 0~C and the mixture was stirred at 0~C for 30 min and at room temp. for 1 h. The mixture was treated with ice. 20 ml of conc. sulfuric acid were then slowly stirred in. The mixture was stirred for a further 5 min. The resulting precipitate was filtered off, washed with water and then taken up in dichloromethane. This solution was extracted with water. The organic phase was evaporated after drying over sodium sulfate.
Crude yield: 4.7 g. The crude product was purified by column chromatography on silica gel (ethyl acetate). Yield: 2.9g (54%) of Example 3c.
1H NMR: (CDCI3) o = 0.69 ppm (s, 3H, CH3); 0.91 (s, 3H, CH3); 1.00 (d, J=6.0 Hz, CH3CH), 0.9-2.4 (m, 24 H, aliphat. CH); 2.99 (s, 3H, CH3SO3); 3.36 (s, 3H, CH30); 3.45 (m, 4H, NH-CH2-CH2-O); 3.86 (br. s, 1 H, CHOH); 3.99 (br. s,1 H, CHOH); 4.50 (br. s,1 H, CHOSO2); 6.05 (br. s, 1H, NH).
.. , ~.. .. .
- Example 3d:
O O
--~NH~OCH3 ~ NH~OCH3 ~l ~X-~ ~ ~/~/
H3C-S-O OH ~O~----OH
3c 3d 1 ml of triethylamine was added to a solution of 2.9 9 (5.3 mmol) of Example 3c and 12.0 9 (80 mmol) of triethylene glycol in 5 ml of dichloromethane. The methylene chloride was distilled off and the mixture was then heated to 100~C. 2 ml of triethylamine were added and the mixture was stirred at 100~C for 5 h.1 ml of triethylamine was then added again and the mixture was stirred at 100~C for a further 8 h. The mixture was allowed to stand at room temp. for 1 week and then dissolved in dichloromethane. The solution was poured into 50 ml of ice water/conc.
sulfuric acid (1:1). This mixture was extracted 3 times with dichloromethane. The organic phase was washed with water, dried over sodium sulfate and evaporated. Crude yield: 2.5 9. The crude material was purified by chromatography on silica gel (gradient ethyl acetate ---> ethyl acetate: methanol = 9:1). Yield: 0.9 9 (30%) of Example 3d.
1H NMR: (CD30D) ~ = 0.70 ppm (s, 3H, CH3); 0.91 (s, 3H, CH3); 1.02 (d, J=6.0 Hz, CH3CH), 0.8-2.5 (m, 24 H, aliphat. CH); 3.25-3.35 (m, 2H, NH-CH2-CH2-O); 3.34 (s, 3H, CH30); 3.41-3.46 (m, 2H, NH-CH2-CH2-O);
3.50-3.67 (m,13H, O-CH2-CH2-O and CHR2OCH2); 3.79 (br. s, 1H, CHOH); 3.95 (br. s,1 H, CHOH).
- Example 3e:
~NH~OCH3 ~,I~NH~~CH3 ~O~ OH TsO~O~OH
3d 3e 900 mg (1.5 mmol) of Example 1d were dissolved in 30 ml of dichloromethane. 343 mg (1.8 mmol) of p-toluenesulfonyl chloride and 140 mg (2.5 mmol) of potassium hydroxide powder were added to this solution at 0~C. The mixture was warmed to room temp. with stirring. After stirring at room temp. for30 min,100 mg (1.8 mmol) of potassium hydroxide powder were again added and the mixture was again stirred for 2 h. The precipitate was filtered off. The filtrate was evaporated. Crude yield: 1.2 g. Pure Example 3e was obtained by column chromatography on silica gel (gradient dichloromethane ---> dichloromethane: methanol = 95:
5). Yield: 870 mg (77%) of 3e.
1H NMR: (CDCI3) o = 0.69 ppm (s, 3H, CH3); 0.90 (s, 3H, CH3); 0.98 (d, J=6.0 Hz, CH3CH),1.0-2.4 (m, 24 H, aliphat. CH); 2.45 (s, 3H, Ts-CH3);
3.36 (s, 3H, CH30); 3.4-3.65 (m,13H, O-CH2-CH2-O, NH-CH2-CH2-O and CHR2OCH2); 3.70 (t, J= 6Hz, 2H, Ts-O-CH2-CH2); 3.84 (br. s,1 H, CHOH);
3.97 (br. s,1H, CHOH); 4.16 (t, J= 6Hz, 2H, O-CH2-CH2); [lacuna]
1 H, CHR2OCH2); 7.35 (d, J=9Hz, 2H, aryl H), 7.80 (d, J=9Hz, 2H, aryl H).
- Example 3f:
2 I m:n=0.99:0.01 x HCI x HCI
--Jl'hH ~NH
~/~/ OCH3 <~)0 ~~/~/ OCH3 TsO~o~J'OH
5 150 mg of polyvinylamine were dissolved in a mixture of 20 ml of water and 20 ml of ethanol. pH = 10 was set.131 mg (5 mol%) of Example 3e were added in portions at 40-50~C. The solution was stirred at room temp. for 4 h and then heated under reflux for 3 h. After allowing to stand for a further 3 days, Example 3e was still detectable. The mixture was adjusted 10 to pH = 12 and then heated under reflux for a further 7 h. After cooling, thepolymeric product was isolated by ultrafiltration (5000A membrane;
ethanol/water = 1 :1) and subsequent freeze-drying. Yield: 180 mg of Example 3f. The 1H NMR analysis showed a degree of substitution of about n = 1 %.
1H NMR (D2O): o = 0.73 ppm (s, 3H, cholate CH3); 0.96 (br. m, 6H, cholate CH3); 0.99 (d, J= 6.0Hz, 3H, CH3CH); 1.0-2.4 (m, aliphat. cholate CH); 1.3-1.8 (br. m, 2H, CHNH-CH2); 2.94-3.16 (br. m,1H, CHNH-CH2); 3.38 (s, 3H, CH30); 3.4-3.9 (O-CH2, N-CH2, O-CH); 3.91 (br. s,1 H, CHOH); 4.08 (br. s, 20 1 H, CHOH).
~ CA 02263671 1999-02-18 Example 4:
5NH2 NH2 NH m: n= 0.95: 0.05 XHa XHa nH (~ H
~/ / OCH3 <)~~~ / O~H3 Tso'~O~OH
100 mg of polyvinylamine were dissolved in a mixture of 20 ml of water and 20 ml of ethanol. pH = 10 was set. 350 mg (20 mol%) of Example 3e were added in portions at 40-50~C. The solution was stirred at room temp. for 4 h and then heated under reflux for 3 h. After allowing to stand for a further 3 days, Example 3e was still detectable. The mixture was adjusted to pH = 12 and then heated under reflux for a further 7 h. After cooling, the polymer product was isolated by ultrafiltration (5000A membrane; ethanol/
water = 1 :1) and subsequent freeze-drying. Yield: 170 mg of Example 3f.
The 1H NMR analysis showed a degree of substitution of about n = 5%.
1H NMR: (D2O) d = 0.73 ppm (s, 3H, cholate CH3); 0.96 (br. m, 6H, cholate CH3); 0.99 (d, J= 6.0Hz, 3H, CH3CH); 1.0-2.4 (m, aliphat. cholate CH); 1.3-1.8 (br. m, 2H, CHNH-CH2); 2.94-3.16 (br. m,1H, CHNH-CH2); 3.38 (s, 3H, CH30); 3.5-3.85 (O-CH2, N-CH2, O-CH); 3.89 (br. s,1 H, CHOH); 4.05 (br.
s,1 H, CHOH).
- Example 5:
+
O NH O NH o Cl~
o~OH
I
= / m: n= 0.57: 0.43 ~ rr-- ~--n O NH O NH 1~l ~~'~0 Na lCI-o~OH
132 mg of 3-methacryloylamidopropyltrimethylammonium chloride were added to a solution of 344 mg of comonomer I (synthesis as described in Pat. EP 548793) in 2 ml of ethanol. Nitrogen was passed into the mixture for 45 min. 662 ,ug of Trigonox 62 (t-butylperoxydiethyl acetate; AKZO
Chemicals) or dibenzoyl peroxide were then added under a nitrogen atmosphere. The mixture was stirred at 75~C for 27 h with exclusion of air.
As starting material was still detectable, 687 ,ug of VA-044 (2,2 -azobis-[2-(2 -cyanovaleric acid)]; 75% strength solution in water; Wako Chemicals) were added under a nitrogen atmosphere. The mixture was stirred at 45-50~C for 20 h. 5 ml of 20% strength aq. sodium hydroxide solution were then added and the mixture was stirred at 45~C for 18 h.
150 ml of water were then added. pH = 7 was set by addition of dilute hydrochloric acid. Example 5 was then isolated by ultrafiltration (5000A
~ CA 02263671 1999-02-18 - membrane; methanol/water = 1 :2).
1H NMR: (D2O) o= 0.73 ppm (s, 3H, cholate CH3); 0.96 (br. m, 6H, cholate CH3); 0.99 (d, J= 6.0Hz, 3H, CH3CH); 1.0-2.4 (m, aliphat. cholate CH); 1.3-1.8 (br. m, 2H, CHNH-CH2); 2.94-3.16 (br. m,1H, CHNH-CH2); 3.38 (s, 3H, CH30); 3.5-3.85 (O-CH2, N-CH2, O-CH); 3.89 (br. s, 1 H, CHOH); 4.05 (br.
s,1 H, CHOH).
Ratio: 57:43 Example 6:
OH ~ ~ OH
NH2 NH +
(CH2),2 ~ >
--IN--_ OH
~ ~OH
NH2NH NH I >
(CH2) 12 ~' --N-- OH
I Cl l: m: n = 0.84: 0.15: 0.01 600 mg of trimethylammoniumdodecyl-substituted polyvinylamine (degree 30 of substitution 20%) were dissolved in a mixture of 10 ml of water and 10 ml of methanol. The mixture was warmed to 45-50~C. 239 mg (10 mol%) of 3-mesylcholic acid (Example 1 a) were then added, the pH
being kept at 8-10 by addition of dilute sodium hydroxide solution. The clear solution was stirred at 45-50~C for 15 h. The product was purified by . . , ultrafiltration (5000A membrane) in methanol/water = 1 :1 and isolated by freeze-drying. Yield: 550 mg.
1H NMR: (D2O) o = 0.8-2.2 (m), 2.25-4.2 (m), 3.04 (s, N-CH3). Degree of substitution as indicated above.
Example 7:
Example 7a:
O O
~OH ; 1~OH
+ Br-(CH2)6~r ~ ,~
HO OH Br--(CH2)6--O OH
12.3 9 (30 mmol) of cholic acid were dissolved in 200 ml of THF. 73.2 9 (300 mmol) of 1,6-dibromohexane were then added and the mixture was heated under reflux.10.2 9 (180 mmol) of potassium hydroxide powder were then added in portions in the course of 6 h. The mixture was then stirred for a further 1 h. After cooling, the resulting precipitate was filteredoff with suction and washed with THF. The filtrate was concentrated.
Excess dibromohexane was distilled off in vacuo. The viscous residue was purified by column chromatography (ethyl acetate -> ethyl acetate:methanol = 9:1). Yield: 6 9 1H NMR: (CDCI3) ~ = 0.68 ppm (s, 3H, cholate CH3); 0.89 (br. m, 6H, cholate CH3); 0.99 (d, J= 6.0Hz, 3H, CH3CH); 1.0-2.4 (m, aliphat. cholate CH); 1.3-1.8 (br. m, 2H, CHNH-CH2); 2.6-2.9 (br. m, 3H); 3.42 (d, J= 6.0Hz, 2H); 3.84 (br. s,1 H, CHOH); 3.96 (br. s,1 H, CHOH); 4.06 (d, J= 6.0Hz, 2H).
MS: Cl (ammonia): m/e[%]= 590 (M+NH4 of 31Br isotope, 95); 588 (M+NH4 - von 79Br isotope, 100).
Example 7b:
O
~ OH I OH
NH2 1 >
X HCI ~
Br--(CH2)6--O~OH O
OH ~OH
NH2 NH--(CH2)6--~ OH
x HCI
m: n= 0.98: 0.02 10 9 of polyallylamine hydrochloride were dissolved in 100 ml of water and the pH was adjusted to pH = 10 using dil. sodium hydroxide solution. 3.1 9 of Example 7a were added at 50-60~C in the course of 3 h, a temporary cloudiness occurring each time. The pH was kept at pH = 9.5-10 by addition of dil. sodium hydroxide solution. The mixture was stirred at 60~C
for 4 h. The product was purified by ultrafiltration in methanol/water = 1:1 and subsequent freeze-drying. Yield: 7.4 9.
1H NMR: (D2O) o = 0.72 (br. s, 3H, cholate CH3), 0.92 (br. s, 3H, cholate CH3), 0.95-2.2 (m, aliphat. CH), 2.72 (br. s, 2H, CH2-NH2), 2.9-4.2 (m, CHOH, CH2O inter alia). Degree of substitution of cholate: 2%.
. CA 02263671 1999-02-18 Example 8:
OH \~OH
~NH N~
Meso~ O OH O
~ OH
~/
MesO l l ~ NH I ~ o~~OH
O
233 mg (0.44 mmol) of 3-(2-mesyl)ethoxycholic acid were dissolved in 1 ml of methanol and 75 mg (0.44 mmol) of 3-(N,N-dimethylaminopropyl)-methacrylamide were then added. After 20 min, a precipitate resulted. The mixture was stirred at 50~C for 14 days. The solvent was stripped off and the residue was chromatographed 3 times on silica gel (methanol ->
methanol/water/acetic acid = 10:0.5:0.05). 50 mg of product were obtained.
1H NMR: (CD30D) ~ = 0.71 (s, 3H, cholate CH3), 0.94 (s, 3H, cholate CH3),1.01 (d, J= 7 Hz, 3H, cholate CH3CH),1.0-2.5 (m, aliphat. CH), 2.80 (s, 3H, mesylate anion), 3.0-4.0 (several m, CHOH, CH2O inter alia), 3.16 (s, 6H, N-CH3), 5.40 (br. s, 1 H, vinyl-H), 5.74 (br. s, 1 H, vinyl-H).
MS: m/e[%]= 605 (M+).
- Example 9:
Example 9a:
o OH \~OH
NH~N~ + ~/
Br--(CH2)6--O~OH
OH
,~,J
O N--(CH2)6--O~OH
251 mg (0.44 mmol) of 3-(6-bromohexyloxy)cholate were dissolved in 2 ml of methanol and 75 mg (0.44 mmol) of 3-(N,N-dimethylaminopropyl)-methacrylamide were then added. The mixture was heated under reflux for 6 h and then allowed to stand overnight. The solvent was stripped off and the residue was chromatographed on silica gel (methanol -> methanol/
water/acetic acid = 99:0.5:0.5).160 mg of crude product were obtained, which was further purified by means of a weakly acidic ion exchanger.
Yield: 80 mg.
1H NMR: (CDCI3) o= 0.67 (s, 3H, cholate CH3), 0.87 (s, 3H, cholate CH3), 0.99 (d, J= 7 Hz, 3H, cholate CH3CH), 1.0-2.4 (m, aliphat. CH), 3.1-4.1 (several m, CHOH, CH2O inter alia), 3.15 (s, 6H, N-CH3), 3.86 (s), 5.35 (br. s,1 H, vinyl-H), 5.85 (br. s,1 H, vinyl-H).
~ CA 02263671 1999-02-18 Example 9b:
o d~NH~ I + + ~OH
O I ) /\~\
~ (CH2)6--~ ./ OH
~ m:n= 0.70:0.30 n O
O NH O NH OH ~O Na (CH2)6--O~
0.52 mg of free radical initiator VA 044 (Wako) was added to a solution of 55 mg (77 I~mol) of Example 9a and 17 mg (77 ,umol) of trimethyl-20 ammoniumpropyl methacrylate chloride in 3 ml of water. The mixture was deaerated and then stirred at 45~C for 70 h. The mixture was evaporated and the residue was dissolved in 10 ml of water and purified by ultrafiltration (5000A membrane). After freeze-drying, 66 mg of Example 9b were obtained.
1H NMR: (CDCI3) ~i = 0.67 (s, 3H, cholate CH3), 0.87 (s, 3H, cholate CH3), 0.99 (d, J= 7 Hz, 3H, cholate CH3CH),1.0-2.4 (m, aiiphat. CH), 3.1-4.1 (several m, CHOH, CH2O inter alia), 3.15 (s, 6H, N-CH3), 3.86 (s), 5.35 (br.
s,1 H, vinyl H), 5.85 (br. s,1 H, vinyl H).
. CA 02263671 1999-02-18 Example 9c:
OH ~OH
~~\
~NH----N--(CH2)6--O~OH
-- ~--n O
O NH OH~O Na ~ Cl J ' (CH2)6--o OH
Nitrogen was passed through a solution of 741 mg (1.0 mmol) of Example 9a in 3.5 ml of methanol for 30 min. The solution was then warmed to 60~C. 10 mg of free radical initiator VA 044 (Wako) were added. The mixture was then stirred at 60~C under a nitrogen atmosphere for 4 h. It was then diluted with water and purified by ultrafiltration (5000 A
membrane). For the exchange of the counterion Br~ - Cl- it was then washed twice with dilute aqueous NaCI solution and then twice with water.
After freeze-drying, 456 mg were obtained.
Elemental analysis:
Calculated: C 66.4 % H 10.4 % N 14.3 % Cl 5.3 %
Found: C 66.2 % H 10.5 % N 14.2 % Cl 5.2 %
~ CA 02263671 1999-02-18 - Example 10:
+
ONH O NH o ~J\OCH3 ~N~
O~OH
m: n = 0.50: 0.50 ~,~--n~ n O NH O NH O
î~ X ' ~ Na x HCI
O~OH
38 mg (0.35 mmol) of N-(3-N,N-dimethylaminopropyl)methacrylamide and 200 mg (0.35 mmol) of comonomer I were dissolved in 1.39 ml of ethanol.
5 Nitrogen was passed into the mixture with stirring for 45 min. 0.66 mg of VA 044 initiator was then added. The mixture was stirred at 45-50~C for 27 h. After cooling, the resulting copolymer was isolated by ultrafiltration in water (5000A membrane) and subsequent freeze-drying. Yield: 196 mg.
.. . .. .. . ..
. CA 02263671 1999-02-18 Example 11:
~--~OCH3 NH2 ~ NH~
l m:n= 0.95 005 OH ~\~O Na _- - ~
~Hi'-- ~H
x HCI
181 mg (3.19 mmol) of allylamine were added at room temp. to a solution of 80 mg (0.17 mmol) of I in 3 ml of ethanol. Nitrogen was passed into the mixture for 1 h. 1.14 mg (1 mol%) of VA 044 initiator were then added. The mixture was stirred at 50~C for 15 h. The mixture was concentrated and the residue was stirred at 70~C for 4 h in 5 ml of 20% strength aq. sodium hydroxide solution. The solution was adjusted to pH = 7. The product was isolated by ultrafiltration in water (5000A membrane) and subsequent freeze-drying. Yield: 106 mg.
... .. . . .
.
- Example 12:
~ m:n= 0.8:0.2 NH2 NH + 1~l x HCI (CH2)10 OH\~OH
--N+ _ I Cl ~/
Br--(CH2)6--O~----'OH
~ ~ OH : I~OH
CH2 CH2 Cl H2 , ~, >
NH2 NH NH ~ T
(CH2) 10 (CH2)6 ~ OH
--N--I Cl-I: m: n = 0.79: 0.20: 0.01 1.74 9 of sodium hydroxide powder were added at room temp. to a solution of 5.00 9 (43 mmol) of I in 100 ml of water. A solution of 1.98 9 of ll in 60 ml of methanol was then added. The mixture was stirred at 60~C for 6 h.
The mixture was diluted to a volume of 21 with water. The pH was adjusted to pH = 7. The product was isolated by ultrafiltration in water (5000A
membrane) and subsequent freeze-drying.
Yield: 5.63 9.
1H NMR (D2O): I: m: n = 0.79: 0.20: 0.01 . CA 02263671 1999-02-18 - Example 13:
~ m: n= 0.8: 0.2 5 NH2 NH + ~
x Ha (CH2)l0 OH \r~ OH
--N+ ~
Cl~
10Br--(CH2)6--O'~ 'OH
OH ~OH
(CHz)lo (CH2)6 ~ OH
I Cl-I: m: n =0.79: 0.20: 0.01 2.22 9 (55.6 mmol) of sodium hydroxide powder were added at room temp.
to a solution of 5.00 9 (55.6 mmol) of I in 100 ml of water. A solution of 2.54 9 of ll in 75 ml of methanol was then added. The mixture was stirred 25 at 60~C for 8 h. The mixture was diluted to a volume of 2 I with water. The pH was adjusted to pH = 7. The product was isolated by ultrafiltration in water (5000A membrane) and subsequent freeze-drying.
Yield: 5.50 9.
1H NMR (D2O): I: m: n = 0.79: 0.20: 0.01 - Example 14:
o ,~OCH3 ~" + ~, xNHHcl ~ NHJ--J'OH
_ _ _ I
~;~ ~ ~ O Na x HCI <> ~~
O NH~OH
m: n = 0.99: 0.01 274 mg (0.50 mmol) of I were added at room temp. to a solution of 107 mg (2.5 mmol) of polyvinylamine in 5 ml of ethanol. The pH of the solution was adjusted to pH = 9-10 and the mixture was stirred at room temp. for 1 week. The mixture was concentrated to a quarter of the volume and treated with 10 ml of 10% strength aqueous sodium hydroxide solution. It was stirred at room temp. for 2 days and the pH was then adjusted to pH = 7.
The product was isolated by ultrafiltration in water (5000A membrane) and subsequent freeze-drying.
Yield: 90 mg.
1H NMR (D2O): m: n = 0.99: 0.01 - Example 15:
Example 15a:
O O
~X ~OH ~OH
~~ + Br-(CH2)~0-Br HO~OH Br--(CH2)l0 O~OH
4.1 g (10 mmol) of cholic acid were dissolved in 100 ml of THF. 9.0 g (30 mmol) of 1,10-dibromodecane were then added and the mixture was 15 heated under reflux. 3.4 g (60 mmol) of potassium hydroxide powder were then added in portions in the course of 5 h. The mixture was then stirred for a further 1 h. After cooling, the resulting precipitate was filtered off with suction and washed with THF. The filtrate was concentrated. Excess dibromodecane was distilled off in vacuo. The viscous residue was purified 20 by column chromatography (ethyl acetate). Yield: 0.81 g . CA 02263671 1999-02-18 Example 15b:
+ ~OH
NH2 1 >
XHa ~
Br--(CH2),0 O~OH O
OH ~OH
NH2 NH--(CH2),0 O OH
x HCI
m: n = 0.99: 0.01 1.5 g of polyallylamine hydrochloride were dissolved in 15 ml of water and 10 ml of methanol and the pH was adjusted to pH = 10 using dil. sodium hydroxide solution. 0.5 g (5 mol%) of Example 1 5a were added at 50-60~C
in the course of 2 h, a temporary cloudiness occurring. The pH was kept at pH = 9.5-10 by addition of dil. sodium hydroxide solution. The mixture was stirred at 60~C for 5 h. The product was purified by ultrafiltration (3000A
membrane) in ethanol/water = 1:1 and then in water and subsequent freeze-drying. Yield: 0.95 g.
1H NMR: (D2O) degree of substitution of cholate: 1%.
. CA 02263671 1999-02-18 - Example 16:
OH ''f--I~OCH3 ~N O O~X/
l O
OH \~O Na _- -O
x HCI m: n = 0.97: 0.03 Nitrogen was passed for 30 min through a solution of 63 mg (0.14 mmol) of methyl 3-acryloylcholate in 2 ml of ethanol. 250 mg (2.60 mmol) of N-vinylimidazole (Polyscience) and 8.9 mg (0.027 mmol) of VA 044 initiator were then added. The mixture was warmed to 45-48~C under nitrogen and stirred at this temperature for 2 days. A viscous material was obtained.
This was dissolved in 10 ml of methanol. 3 ml of 20% strength aqueous sodium hydroxide solution were then added and the mixture was stirred at 50~C for 12 h. The pH was adjusted to pH = 7. The product was isolated by ultrafiltration (5000A membrane) in water and subsequent freeze-drying.
Yield: 200 mg.
1H NMR: (D2O) degree of substitution of cholate: 3%.
. CA 02263671 1999-02-18 Example 17:
OH \~\/ OH
S ,~ +
MesO OH
l O
~k ~OH
X HCI --/
~1~ OH
m: n= 0.99: 0.01 500 mg of polyvinylamine were dissolved in a mixture of 10 ml of water and 10 ml of ethanol. 57 mg of 3-mesylcholic acid were added in portions at 40-50~C. The pH was kept between 9 and 10. The mixture was stirred at 40-50~C for 9 h. 200 ml of ethanol:water = 1 :1 were then added. The product was isolated by ultrafiltration (5000A membrane) in water and subsequent freeze-drying.
Yield: 500 mg.
1H NMR: (D2O) degree of substitution of cholate: 1%.
, - Example 18:
+
O NH O NH o O~OH
m: n= 0.50: 0.50 --rr-- ~--n O NH O NH O
~ ~ ~ O Na x HCI
O--/~OH
139 mg (0.63 mmol) of 3-methacrylamidopropyltrimethylammonium chloride and 4.1 mg (0.013 mmol) of VA 044 initiator were added to a deaerated solution of 300 mg (0.63 mmol) of methyl 3-acryloylcholate in 2.1 ml of ethanol. The mixture was stirred at 45-48~C for 2 days under nitrogen. Monomers were no longer detectable on TLC checking. The pH
was adjusted to pH = 7 and 50 ml of water were added. The product was isolated by ultrafiltration (5000A membrane) in water and subsequent freeze-drying. Yield: 370 mg.10 ml of THF and 1 ml of 20% strength sodium hydroxide solution were added to this product. The mixture was warmed at 50~C. Since a homogeneous solution was not obtained, the THF was distilled off in vacuo.100 ml of water were added and the mixture was stirred at room temp. ovemight. The pH was adjusted to pH = 7.
Example 18 was then isolated by ultrafiltration (5000A membrane;
- methanol/water = 1 :1 ) and subsequent freeze-drying.
1H NMR: (D2O): ratio:70:30.
In the bovine bile assay adsorption test, the ability of the polymer to adsorb bile acids is measured.
Bovine bile assay adsorption test:
The samples were prepared as follows:
An aqueous solution is first prepared which contains the following salts in the concentrations indicated below:
NaCI 90 mmol/l KCI 6 mmol/l CaCI2 3 mmol/l NaHCO3 10 mmol/l Sodium taurocholate1.38 g/l Sodium glycocholate2.49 g/l The pH of the solution is adjusted to pH = 7.0 + 0.2.
25 10 ml of the above solution are taken and added to a sample vessel.
20 mg of the polymer (Examples 1 to 18) are then added. The mixture is slowly stirred for 2 h and then centrifuged (5000 rpm). A sample of 30 ,ul is taken from the supernatant for analysis and analyzed as described in the following.
- HPLC with FLUORESCENCE DETECTiON
Equipment: HPLC unit from Kontron, consisting of three pumps and mixing chamber, autosampler, UV detector and analysis unit with MT2 software.
Fluorescence detector from Merck-Hitachi As the samples are light- and temperature-sensitive, the autosampler is cooled to about 5~C.
Mobile phase: Eluent A: ~'Millipore water (own unit) Eluent B: acetonitrile/methanol 60:30 Column: ~'LiChrospher 100 RP-18, 25 mm, 5 ,um from Merck Precolumn: LiChrospher 60 RP-select B, 4 mm, 5,um from Merck Flow rate: 1.3 ml/min Detection: Excitation: 340 nm Emission: 410 nm Gradient: 0.00 min 66 % B
7.50 min 66 % B
8.00 min 76 % B
12.50 min 76 % B
13.00 min 83 % B
25.00 min 83 % B
25.50 min 91 % B
40.00 min 91 % B
~ CA 02263671 1999-02-18 Enzymatic determination of the total bile acid - 900 ~l each of the following mixture are added to Eppendorf vessels:
6 ml of tetrasodium diphosphate buffer 0.1 M, pH 8.9, 2 ml of NAD solution (4 mg/ml of water), 20 ml of Millipore water - 30 ,ul of the sample (concentration: 2 mg of polymer per 1 ml of water) and 30 ,ul of enzyme solution are pipetted in.
10 - Enzyme solution: 3-alpha-hydroxysteroid dehydrogenase 0.5 units/ml - The batches are mixed and incubated at room temperature for 2 h.
- Subsequent transfer to 1 ml disposable cuvettes and measurement in a photometer at 340 nm.
Results of the enzyme test Substance Adsorption Ex. 7b 53 %
Ex. 14 52 %
Cholestyramine 33 %
Substance from EP 5 %
0549 967, Example 15 HPLC with UV DETECTION
Equipment: HPLC unit from Kontron, consisting of three pumps and mixing chamber, autosampler, UV detector and analysis unit with MT2 software.
Mobile phase: Eluent A: ammonium carbamate buffer 0.019 M, adjusted to pH 4.0 with phosphoric acid.
Eluent B: acetonitrile Column: LiChrospher 100 RP-8, 25 mm, 5 ,um from Merck Precolumn: LiChrospher 60 RP-select B, 4 mm, 5,um from Merck Flow rate: Gradient: 0.00 min 0.8 ml/min 20.00 min 0.8 ml/min 23.00 min 1.3 ml/min 51.00 min 1.3 ml/min Detection: 200 nm (for preparations additionally at 254 nm) G radient: 0.00 min 32 % B
8.00min 35%B
17.00 min 38 % B
20.00 min 40 % B
24.00 min 40 % B
30.00min 50%B
45.00min 60%B
. CA 02263671 1999-02-18 . ~ ....
Binding of the bile acids [%]
CholestyramineExample 6 Example 17 Taurocholate (TC) 52 57 57 Glycocholate (GC) 34 50 48 Taurodeoxycholate (TDC) 86 93 89 Glycodeoxycholate (GDC) 74 90 88 Taurochenodeoxycholate (TCDC) 100 100 100 Glycochenodeoxycholate (GCDC) 77 89 84 The "in vivo perfused rat intestine" test investigates the ability of the polymers to block the bile acid reabsorption in the region of the ileum.
In vivo perfused rat intestine:
The in vivo investigation was carried out as described in F.G.J. Poelma et al. (J. Pharm. Sci. 78 (4), 285-89,1989) - modifications of the test are indicated.
Taurocholate and taurocholic acid, and cholate and cholic acid, respectively, are used synonymously in the investigations.
Cannulation of the bile duct The bile duct is exposed and a catheter is tied in (PE 50, Intramedic~). An adaptor to accept 100 ~I disposal pipette tips (Brandt) is attached to its end. The bile is collected in these pipettes and filled into weighed Eppendorf reaction vessels at specific time intervals. At the end of the experiments, the bile, as well as the medium samples, are weighed and aliquots are measured in a scintillation counter. To this end,10 ~l of sample are pipetted into a Sarstedt sample vessel, 58 x 22 mm, with 10 ml of Quickszint 212 (Zinsser GmbH, Frankfurt am Main, Germany) and counted in a Beckman 2800 t3-counter after a 30 min decay time.
1. The compounds according to the invention, Examples 1 to 18, were CA 0226367l l999-02-l8 instilled into the intestinal segment together with 10 mM taurocholate using 3H-taurocholate or 14C-taurocholate as tracer and the perfusion solution was circulated for 2 h with the aid of a peristaltic pump. The decrease in the tracer in the intestine (medium) or the appearance of the tracer in the bile fluid (bile) was determined with the aid of scintillation measurements and HPLC.10 mM taurocholate with the tracer without compound according to the invention was installed as control and the change in the intestine and in the bile fluid was determined.
2. In vivo perfused intestine The experimental animals used are Wistar rats bred in-house (Hoechst animal husbandry) with an average body weight of 230-290 9. The experimental animals are not fasted before anesthesia (urethane 1 g/kg i.p.). After the onset of anesthesia, the animals are fixed to a temperature-controlled (constant 37~C) operating table (Medax), shaved on the ventral side and then the abdominal wall of the animals is opened using an incision about 7 cm long. A Luer adaptor (Hoechst precision mechanics) is then tied into the lower intestine about 8 cm from the ileocecal flap and the continuing small intestine is tied off here. Further tying-in and tying-off of the small intestine is then carried out 13-14 cm from the beginning of the small intestine. The contents of this intestinal segment are carefully rinsed out with warm isotonic saline solution at 37~C. The experimental solution is later instilled into this segment, the end part of the jejunum/beginning of the ileum.
The pump tubing is first filled from the 2 ml of installation solution (10 mM
taurocholate, polymer (Example 1 to18) in a concentration of 0.1 mmol/l in 0.9% strength phosphate-buffered saline solution, tracer: 3.5 ,uCi [3H(G)]-taurocholic acid, NET-322, Lot 2533-081, DuPont de Nemour GmbH, Dreieich, Germany, dissolved in phosphate-buffered isotonic saline solution (silicone tubing A, 0.5 mm Desaga, Heidelberg, Germany, order No.132020). The pump tubing is then attached to the intestinal segment using two Luer adaptors and the residual solution is instilled via a three-way tap (Pharmaseal K 75a) and a 2 ml disposable syringe (Chirana).
Immediately afterwards, the peristaltic pump (LKB Multiperpex 2115) is switched on, and the medium is recirculated at 0.25 ml/min. A sample for measurement of the activity (decrease in radioactivity in the intestine =
5 absorption rate) is taken at regular intervals by means of a Hamilton syringe and a cannula (Termo 0.4 x 20) from an infusion tube integrated into the circuit.
To demonstrate the prolonged action of the oligomeric or polymeric bile 10 acids, in this special experimental design the outflow (intestine) and the filling (bile) of the radioactive tracer is tested with inhibitor during the first instillation (Inst. l) and without the inhibitor during the second instillation (Inst. ll).
Cholestyramine: 25% inhibition of absorption Example 6: 36% inhibition of absorption Example 7b: 50% inhibition of absorption Example 15b: 60% inhibition of absorption 20 Evaluation of the tests The bovine bile assay adsorption test shows that the polymers according to the invention have a distinctly greater ability to adsorb bile acids than the substance of Example 15 from EP 0 549 967. The ability of the polymers 25 according to the invention to adsorb bile acids is similar to that of cholestyramine.
In the test system "in vivo perfused rat intestine", the polymers according to the invention show an absorption-inhibiting action of 36% to 60%. In contrast, cholestyramine shows a smaller absorption-inhibiting action of 30 25%. The polymers according to the invention are thus superior even to cholestyramine in their action, as in addition to a great ability to adsorb bileacids, they are themselves readily bound to the bile acid receptor, and thus show an absorption-inhibiting action.
12.50 min 76 % B
13.00 min 83 % B
25.00 min 83 % B
25.50 min 91 % B
40.00 min 91 % B
~ CA 02263671 1999-02-18 Enzymatic determination of the total bile acid - 900 ~l each of the following mixture are added to Eppendorf vessels:
6 ml of tetrasodium diphosphate buffer 0.1 M, pH 8.9, 2 ml of NAD solution (4 mg/ml of water), 20 ml of Millipore water - 30 ,ul of the sample (concentration: 2 mg of polymer per 1 ml of water) and 30 ,ul of enzyme solution are pipetted in.
10 - Enzyme solution: 3-alpha-hydroxysteroid dehydrogenase 0.5 units/ml - The batches are mixed and incubated at room temperature for 2 h.
- Subsequent transfer to 1 ml disposable cuvettes and measurement in a photometer at 340 nm.
Results of the enzyme test Substance Adsorption Ex. 7b 53 %
Ex. 14 52 %
Cholestyramine 33 %
Substance from EP 5 %
0549 967, Example 15 HPLC with UV DETECTION
Equipment: HPLC unit from Kontron, consisting of three pumps and mixing chamber, autosampler, UV detector and analysis unit with MT2 software.
Mobile phase: Eluent A: ammonium carbamate buffer 0.019 M, adjusted to pH 4.0 with phosphoric acid.
Eluent B: acetonitrile Column: LiChrospher 100 RP-8, 25 mm, 5 ,um from Merck Precolumn: LiChrospher 60 RP-select B, 4 mm, 5,um from Merck Flow rate: Gradient: 0.00 min 0.8 ml/min 20.00 min 0.8 ml/min 23.00 min 1.3 ml/min 51.00 min 1.3 ml/min Detection: 200 nm (for preparations additionally at 254 nm) G radient: 0.00 min 32 % B
8.00min 35%B
17.00 min 38 % B
20.00 min 40 % B
24.00 min 40 % B
30.00min 50%B
45.00min 60%B
. CA 02263671 1999-02-18 . ~ ....
Binding of the bile acids [%]
CholestyramineExample 6 Example 17 Taurocholate (TC) 52 57 57 Glycocholate (GC) 34 50 48 Taurodeoxycholate (TDC) 86 93 89 Glycodeoxycholate (GDC) 74 90 88 Taurochenodeoxycholate (TCDC) 100 100 100 Glycochenodeoxycholate (GCDC) 77 89 84 The "in vivo perfused rat intestine" test investigates the ability of the polymers to block the bile acid reabsorption in the region of the ileum.
In vivo perfused rat intestine:
The in vivo investigation was carried out as described in F.G.J. Poelma et al. (J. Pharm. Sci. 78 (4), 285-89,1989) - modifications of the test are indicated.
Taurocholate and taurocholic acid, and cholate and cholic acid, respectively, are used synonymously in the investigations.
Cannulation of the bile duct The bile duct is exposed and a catheter is tied in (PE 50, Intramedic~). An adaptor to accept 100 ~I disposal pipette tips (Brandt) is attached to its end. The bile is collected in these pipettes and filled into weighed Eppendorf reaction vessels at specific time intervals. At the end of the experiments, the bile, as well as the medium samples, are weighed and aliquots are measured in a scintillation counter. To this end,10 ~l of sample are pipetted into a Sarstedt sample vessel, 58 x 22 mm, with 10 ml of Quickszint 212 (Zinsser GmbH, Frankfurt am Main, Germany) and counted in a Beckman 2800 t3-counter after a 30 min decay time.
1. The compounds according to the invention, Examples 1 to 18, were CA 0226367l l999-02-l8 instilled into the intestinal segment together with 10 mM taurocholate using 3H-taurocholate or 14C-taurocholate as tracer and the perfusion solution was circulated for 2 h with the aid of a peristaltic pump. The decrease in the tracer in the intestine (medium) or the appearance of the tracer in the bile fluid (bile) was determined with the aid of scintillation measurements and HPLC.10 mM taurocholate with the tracer without compound according to the invention was installed as control and the change in the intestine and in the bile fluid was determined.
2. In vivo perfused intestine The experimental animals used are Wistar rats bred in-house (Hoechst animal husbandry) with an average body weight of 230-290 9. The experimental animals are not fasted before anesthesia (urethane 1 g/kg i.p.). After the onset of anesthesia, the animals are fixed to a temperature-controlled (constant 37~C) operating table (Medax), shaved on the ventral side and then the abdominal wall of the animals is opened using an incision about 7 cm long. A Luer adaptor (Hoechst precision mechanics) is then tied into the lower intestine about 8 cm from the ileocecal flap and the continuing small intestine is tied off here. Further tying-in and tying-off of the small intestine is then carried out 13-14 cm from the beginning of the small intestine. The contents of this intestinal segment are carefully rinsed out with warm isotonic saline solution at 37~C. The experimental solution is later instilled into this segment, the end part of the jejunum/beginning of the ileum.
The pump tubing is first filled from the 2 ml of installation solution (10 mM
taurocholate, polymer (Example 1 to18) in a concentration of 0.1 mmol/l in 0.9% strength phosphate-buffered saline solution, tracer: 3.5 ,uCi [3H(G)]-taurocholic acid, NET-322, Lot 2533-081, DuPont de Nemour GmbH, Dreieich, Germany, dissolved in phosphate-buffered isotonic saline solution (silicone tubing A, 0.5 mm Desaga, Heidelberg, Germany, order No.132020). The pump tubing is then attached to the intestinal segment using two Luer adaptors and the residual solution is instilled via a three-way tap (Pharmaseal K 75a) and a 2 ml disposable syringe (Chirana).
Immediately afterwards, the peristaltic pump (LKB Multiperpex 2115) is switched on, and the medium is recirculated at 0.25 ml/min. A sample for measurement of the activity (decrease in radioactivity in the intestine =
5 absorption rate) is taken at regular intervals by means of a Hamilton syringe and a cannula (Termo 0.4 x 20) from an infusion tube integrated into the circuit.
To demonstrate the prolonged action of the oligomeric or polymeric bile 10 acids, in this special experimental design the outflow (intestine) and the filling (bile) of the radioactive tracer is tested with inhibitor during the first instillation (Inst. l) and without the inhibitor during the second instillation (Inst. ll).
Cholestyramine: 25% inhibition of absorption Example 6: 36% inhibition of absorption Example 7b: 50% inhibition of absorption Example 15b: 60% inhibition of absorption 20 Evaluation of the tests The bovine bile assay adsorption test shows that the polymers according to the invention have a distinctly greater ability to adsorb bile acids than the substance of Example 15 from EP 0 549 967. The ability of the polymers 25 according to the invention to adsorb bile acids is similar to that of cholestyramine.
In the test system "in vivo perfused rat intestine", the polymers according to the invention show an absorption-inhibiting action of 36% to 60%. In contrast, cholestyramine shows a smaller absorption-inhibiting action of 30 25%. The polymers according to the invention are thus superior even to cholestyramine in their action, as in addition to a great ability to adsorb bileacids, they are themselves readily bound to the bile acid receptor, and thus show an absorption-inhibiting action.
Claims (14)
1. A vinyl copolymer consisting of units of the formula I
and its physiologically tolerable salts, in which:
R1, R2, R3 are hydrogen or CH3;
R4, R5 are hydrogen, (C1-C6)-alkyl, (C1-C6)-acyl;
d is 0.01 to 1.00;
e is 0 to 0.99;
f is 0 to 0.99;
where d + e + f must be equal to 1;
L is a bond, -NH-, -N(CH3)-, - +NH2Cl- -, - +NH(CH3)Cl- -, - +N(CH3)2Cl- -, -NH-CO-, -NH-(CH2)n-, -NH-[(CH2)n-O-]m-(CH2)p-, -NH-(CH2)n-CO-, -NH-CO-(CH2)p-, -NH-(CH2)n-CO-NH(cH2)m-N-(CH3)2+Cl- -(CH2)m-, -NH-[CH2-CH(CH3)-O-]m-CH2-CH(CH3)-, -NH-(CH2)m-N(cH3)2+Cl- -(CH2)n-, -O-(CH2)n-, -O-(CH2)n-CO-, -CO-, -CO-NH-, -CO-N(CH3)-, -CO-NH-CO-, -CO-NH-(CH2)n-, -CO-NH-[(CH2)n-O-]m-(CH2)p-, 54a -CO-NH-(CH2)n-CO-, -CO-NH-CO-(CH2)n-, -CO-NH-[CH2-CH(CH3)-O-]m-CH2-CH(CH3)-, -CO-NH-(CH2)m- +N(CH3)2Cl- -(CH2)n-, -CO-(CH2)n-O-(CH2)p-CO-, -Ar-, -Ar-CO-, -Ar-CH2-, -Ar-CH2- +N(CH3)2Cl- -(CH2)n-, -CO-Ar-CO-, -(C1-C12)-alkylene-, -NH-Ar-CO-, -NH-CH2-Ar-CH2-, -NH-CO-Ar-CO-;
H is a bond, -CH2-, -Ar-, -Ar-CH2-, where Ar is phenylene, naphthylene;
m is 1 to 18;
n is 1 to 18;
p is 1 to 18;
A is -O-, -NH-, a bond;
B is -OH, -ONa, -OK, -NH2, -NH-CH3, -N(CH3)2, -NH-CH2-CH2- SO3Na, -NH-CH2-COONa, -NH-CH2-CH2- +N(CH3)3Cl-, -O- (C1-C18)-alkyl, -NH-(C1-C6)-alkyl, NH-(C1-C6)-alkYlene-OMe, ;
55a R7 is -OH, -O-(C1-C6)-alkyl, -NH2;
Y is -NH2, - +NH3Cl- -, -NH-R9, - +NH2R9Cl- -, -NR9R10, - +NR9R10R11Cl-, -(C1-C18)-alkylene-NH2-, -(C1-C18)-alkylene- +NH3Cl- -, -(C1-C18)-alkylene-NHR9, -(C1-C18)-alkylene-NR9R10, -(C1-C18)-alkylene- +NR9R10R11Cl-, -NH-CO-(C1-C18)-alkyl, -NH-CO-(C1-C12)-alkylene-NR9R10, CO-(C1-C12)-alkylene- +NR9R10R11Cl-, -CO-NH-(C1-C18)-alkylene- +NR9R10R11Cl-, -phenyl, -phenylene-(C0-C6)-alkylene-NH2, -phenylene-(C0-C6)-alkylene-NH-R9, -phenylene-(C0-C6)-alkylene-NR9R10, -phenylene-(C0-C6)-alkylene- +NR9R10R11Cl-, -CO-NH-R9, -NH-(C1-C18)-alkylene-NHR9, -NH-(C1-C18)-alkylene-NR9R10, -NH-(C1-C18)-alkylene- +NR9R10R11Cl-, -CONH2, -CO-(C1-C12)-alkyl, -O-CO-(C1-C12)-alkylene-NR9R10, -O-CO-(C1-C12)-alkylene-+NR9R10R11Cl-, , , , , , , , 56a , ;
Z is -NH2, - +NH3Cl- -, -NH-R9, - +NH2R9Cl- -, -NR9R10, - +NR9R10R11Cl-, -(C1-C18)-alkylene-NH2-, -(C1-C18)-alkylene- +NH3Cl- -, -(C1-C18)-alkylene-NHR9, -(C1-C18)-alkylene-NR9R10, -(C1-C18)-alkylene-+NR9R10R11Cl-, -NH-CO-(C1-C18)-alkyl, -NH-CO-(C1-C12)-alkylene-NR9R10, -NH-CO-(C1-C12)-alkylene- +NR9R10R11Cl- -, -COR9, -CO-OR9, -CO-NH-(C1-C18)-alkylene- +NR9R10R11Cl- -, -phenyl, -phenylene-(C0-C6)-alkylene-NH2, -phenylene-(C0-C6)-alkylene-NH-R9, -phenylene-(C0-C6)-alkylene-NR9R10, -phenylene-(C0-C6)-alkylene- +NR9R10R11Cl-, -CO-NH-(C1-C12)-alkyl, -NH-(C1-C18)-alkylene-NHR9, -NH-(C1-C18)-alkylene-NR9R10, -NH-(C1-C18)-alkylene-+NR9R10R11Cl-, -COOH, -O-R9,-CONH2,-O-CO-R9, -CO-(C1-C12)-alkyl, -O-CO-(C1-C12)-alkylene-NR9R10, -O-CO-(C1-C12)-alkylene-+NR9R10R11Cl-;
, , , 57a , , , , , or a crosslinker selected from the group consisting of:
, , , , , 58a ;
X is O, -NH-;
R9, R10 are (C1-C18)-alkyl-, -phenyl, -CH2-phenyl;
R11 is H, (C1-C18)-alkyl-, -phenyl, -CH2-phenyl;
where at least one of the radicals L, Y and Z must contain an ammonium center.
and its physiologically tolerable salts, in which:
R1, R2, R3 are hydrogen or CH3;
R4, R5 are hydrogen, (C1-C6)-alkyl, (C1-C6)-acyl;
d is 0.01 to 1.00;
e is 0 to 0.99;
f is 0 to 0.99;
where d + e + f must be equal to 1;
L is a bond, -NH-, -N(CH3)-, - +NH2Cl- -, - +NH(CH3)Cl- -, - +N(CH3)2Cl- -, -NH-CO-, -NH-(CH2)n-, -NH-[(CH2)n-O-]m-(CH2)p-, -NH-(CH2)n-CO-, -NH-CO-(CH2)p-, -NH-(CH2)n-CO-NH(cH2)m-N-(CH3)2+Cl- -(CH2)m-, -NH-[CH2-CH(CH3)-O-]m-CH2-CH(CH3)-, -NH-(CH2)m-N(cH3)2+Cl- -(CH2)n-, -O-(CH2)n-, -O-(CH2)n-CO-, -CO-, -CO-NH-, -CO-N(CH3)-, -CO-NH-CO-, -CO-NH-(CH2)n-, -CO-NH-[(CH2)n-O-]m-(CH2)p-, 54a -CO-NH-(CH2)n-CO-, -CO-NH-CO-(CH2)n-, -CO-NH-[CH2-CH(CH3)-O-]m-CH2-CH(CH3)-, -CO-NH-(CH2)m- +N(CH3)2Cl- -(CH2)n-, -CO-(CH2)n-O-(CH2)p-CO-, -Ar-, -Ar-CO-, -Ar-CH2-, -Ar-CH2- +N(CH3)2Cl- -(CH2)n-, -CO-Ar-CO-, -(C1-C12)-alkylene-, -NH-Ar-CO-, -NH-CH2-Ar-CH2-, -NH-CO-Ar-CO-;
H is a bond, -CH2-, -Ar-, -Ar-CH2-, where Ar is phenylene, naphthylene;
m is 1 to 18;
n is 1 to 18;
p is 1 to 18;
A is -O-, -NH-, a bond;
B is -OH, -ONa, -OK, -NH2, -NH-CH3, -N(CH3)2, -NH-CH2-CH2- SO3Na, -NH-CH2-COONa, -NH-CH2-CH2- +N(CH3)3Cl-, -O- (C1-C18)-alkyl, -NH-(C1-C6)-alkyl, NH-(C1-C6)-alkYlene-OMe, ;
55a R7 is -OH, -O-(C1-C6)-alkyl, -NH2;
Y is -NH2, - +NH3Cl- -, -NH-R9, - +NH2R9Cl- -, -NR9R10, - +NR9R10R11Cl-, -(C1-C18)-alkylene-NH2-, -(C1-C18)-alkylene- +NH3Cl- -, -(C1-C18)-alkylene-NHR9, -(C1-C18)-alkylene-NR9R10, -(C1-C18)-alkylene- +NR9R10R11Cl-, -NH-CO-(C1-C18)-alkyl, -NH-CO-(C1-C12)-alkylene-NR9R10, CO-(C1-C12)-alkylene- +NR9R10R11Cl-, -CO-NH-(C1-C18)-alkylene- +NR9R10R11Cl-, -phenyl, -phenylene-(C0-C6)-alkylene-NH2, -phenylene-(C0-C6)-alkylene-NH-R9, -phenylene-(C0-C6)-alkylene-NR9R10, -phenylene-(C0-C6)-alkylene- +NR9R10R11Cl-, -CO-NH-R9, -NH-(C1-C18)-alkylene-NHR9, -NH-(C1-C18)-alkylene-NR9R10, -NH-(C1-C18)-alkylene- +NR9R10R11Cl-, -CONH2, -CO-(C1-C12)-alkyl, -O-CO-(C1-C12)-alkylene-NR9R10, -O-CO-(C1-C12)-alkylene-+NR9R10R11Cl-, , , , , , , , 56a , ;
Z is -NH2, - +NH3Cl- -, -NH-R9, - +NH2R9Cl- -, -NR9R10, - +NR9R10R11Cl-, -(C1-C18)-alkylene-NH2-, -(C1-C18)-alkylene- +NH3Cl- -, -(C1-C18)-alkylene-NHR9, -(C1-C18)-alkylene-NR9R10, -(C1-C18)-alkylene-+NR9R10R11Cl-, -NH-CO-(C1-C18)-alkyl, -NH-CO-(C1-C12)-alkylene-NR9R10, -NH-CO-(C1-C12)-alkylene- +NR9R10R11Cl- -, -COR9, -CO-OR9, -CO-NH-(C1-C18)-alkylene- +NR9R10R11Cl- -, -phenyl, -phenylene-(C0-C6)-alkylene-NH2, -phenylene-(C0-C6)-alkylene-NH-R9, -phenylene-(C0-C6)-alkylene-NR9R10, -phenylene-(C0-C6)-alkylene- +NR9R10R11Cl-, -CO-NH-(C1-C12)-alkyl, -NH-(C1-C18)-alkylene-NHR9, -NH-(C1-C18)-alkylene-NR9R10, -NH-(C1-C18)-alkylene-+NR9R10R11Cl-, -COOH, -O-R9,-CONH2,-O-CO-R9, -CO-(C1-C12)-alkyl, -O-CO-(C1-C12)-alkylene-NR9R10, -O-CO-(C1-C12)-alkylene-+NR9R10R11Cl-;
, , , 57a , , , , , or a crosslinker selected from the group consisting of:
, , , , , 58a ;
X is O, -NH-;
R9, R10 are (C1-C18)-alkyl-, -phenyl, -CH2-phenyl;
R11 is H, (C1-C18)-alkyl-, -phenyl, -CH2-phenyl;
where at least one of the radicals L, Y and Z must contain an ammonium center.
2. A compound as claimed in claim 1, wherein in formula I:
R1, R2, R3 are hydrogen or CH3;
R4, R5 are hydrogen;
d is 0.01 to 1.00;
e is 0 to 0.99;
f is 0 to 0.99;
where d+e+f must be equal to 1;
L is-NH-,-NH-(C1-C18)alkylene-,-NH-((C1-C3)-alkylene-O-)1-18-(C1-C3)-alkylene-, -CO-NH-, -CO-NH-(C1-C18)-alkylene-, , ;
59a H is a bond, -CH2-;
A is -O-, a bond, -NH-;
B is -OH, -ONa, -OCH3, -NH-CH2-CH2-OCH3, ;
Y is NH2, -NHR9, -NR9R10, -+NR9R10R11Cl-, -NH-(C1-C18)-alkylene- +NR9R10R11C1-, -CH2-NH2, -CH2-NH-R9, -(CH2)-NH-(C1-C18)-alkylene-NR9R10, -CH2-NH-(C1-C18)-alkylene-+NR9R10R11Cl-, -NH-CO-R9, -CO-NH-propylene- +NR9R10R11Cl-, , , , -CO-O-(C1-C18)-alkylene-NR9R10;
Z is -NH2, -NHR9, -NR9R10, -CH2-NH2, -CH2-NH-R9, -CH2-NR9R10, -CH2-NH-(C1-C18)-alkylene- +NR9R10R11Cl-, or a crosslinker selected from the group consisting of:
, 60a X is -O-, -NH-;
R9, R10, R11 are (C1-C6)-alkyl-, -phenyl, -CH2-phenyl, where at least one of the radicals L, Y and Z must contain an ammonium center.
R1, R2, R3 are hydrogen or CH3;
R4, R5 are hydrogen;
d is 0.01 to 1.00;
e is 0 to 0.99;
f is 0 to 0.99;
where d+e+f must be equal to 1;
L is-NH-,-NH-(C1-C18)alkylene-,-NH-((C1-C3)-alkylene-O-)1-18-(C1-C3)-alkylene-, -CO-NH-, -CO-NH-(C1-C18)-alkylene-, , ;
59a H is a bond, -CH2-;
A is -O-, a bond, -NH-;
B is -OH, -ONa, -OCH3, -NH-CH2-CH2-OCH3, ;
Y is NH2, -NHR9, -NR9R10, -+NR9R10R11Cl-, -NH-(C1-C18)-alkylene- +NR9R10R11C1-, -CH2-NH2, -CH2-NH-R9, -(CH2)-NH-(C1-C18)-alkylene-NR9R10, -CH2-NH-(C1-C18)-alkylene-+NR9R10R11Cl-, -NH-CO-R9, -CO-NH-propylene- +NR9R10R11Cl-, , , , -CO-O-(C1-C18)-alkylene-NR9R10;
Z is -NH2, -NHR9, -NR9R10, -CH2-NH2, -CH2-NH-R9, -CH2-NR9R10, -CH2-NH-(C1-C18)-alkylene- +NR9R10R11Cl-, or a crosslinker selected from the group consisting of:
, 60a X is -O-, -NH-;
R9, R10, R11 are (C1-C6)-alkyl-, -phenyl, -CH2-phenyl, where at least one of the radicals L, Y and Z must contain an ammonium center.
3. A compound as claimed in claim 1 or 2, wherein in formula I:
R1, R2, R3 are hydrogen;
R4, R5 are hydrogen;
d is 0.01 to 0.5;
e is 0 to 0.99;
f is 0 to 0.99;
where d+e+f must be equal to 1;
L is-NH-CH2-CH2-O-CH2-CH2-O-CH2-CH2-, -NH-(C1-C18)-alkylene-, -CO-, -NH-, -(C1-C6)-alkylene-NH-(C1-C6)-alkylene-;
61a H is a bond, -CH2-;
A is -O-, -NH-, a bond;
B is -OH, -ONa, -NH-CH2-CH2-OCH3;
Y is -NH2, -NHR9, -NH-(C1-C18)-alkylene-+N(CH3)3Cl-, -CO-NH-(C1-C10)-alkylene-+N(CH3)3Cl-, -CO-NH-(C1-C6)-alkylene-N(CH3), -CH2-NH2, -CH2-NHR9;
Z is -NH2, -NHR9, -CH2-NH2, -CH2NHR9,-NH-(C1-C18)-alkylene-+N-(CH3)3Cl-, -CH2-NH-(C1-C18)-alkylene-+N-(CH3)3Cl-, -CO-NH-propylene-+N(CH3)3Cl-;
where at least one of the radicals L, Y and Z must contain an ammonium center.
R1, R2, R3 are hydrogen;
R4, R5 are hydrogen;
d is 0.01 to 0.5;
e is 0 to 0.99;
f is 0 to 0.99;
where d+e+f must be equal to 1;
L is-NH-CH2-CH2-O-CH2-CH2-O-CH2-CH2-, -NH-(C1-C18)-alkylene-, -CO-, -NH-, -(C1-C6)-alkylene-NH-(C1-C6)-alkylene-;
61a H is a bond, -CH2-;
A is -O-, -NH-, a bond;
B is -OH, -ONa, -NH-CH2-CH2-OCH3;
Y is -NH2, -NHR9, -NH-(C1-C18)-alkylene-+N(CH3)3Cl-, -CO-NH-(C1-C10)-alkylene-+N(CH3)3Cl-, -CO-NH-(C1-C6)-alkylene-N(CH3), -CH2-NH2, -CH2-NHR9;
Z is -NH2, -NHR9, -CH2-NH2, -CH2NHR9,-NH-(C1-C18)-alkylene-+N-(CH3)3Cl-, -CH2-NH-(C1-C18)-alkylene-+N-(CH3)3Cl-, -CO-NH-propylene-+N(CH3)3Cl-;
where at least one of the radicals L, Y and Z must contain an ammonium center.
4. A process for the preparation of the compounds as claimed in one or more of claims 1 to 3, which comprises copolymerizing polyvinylamine, to which a cholic acid or a cholic acid derivative is bonded via a linker, with polyvinylamine or substituted polyvinylamine.
5. A pharmaceutical comprising one or more of the compounds as claimed in one or more of claims 1 to 3.
6. A pharmaceutical comprising one or more of the compounds as claimed in one or more of claims 1 to 3 and one or more hypolipidemic active compounds.
7. A compound as claimed in one or more of claims 1 to 3 for use as a hypolipidemic medicament.
8. A process for the production of a pharmaceutical comprising one or more of the compounds as claimed in one or more of claims 1 to 3.
9. The use of the compounds as claimed in one or more of claims 1 to 3 as pharmaceuticals, as pharmaceutical preparations, foodstuffs additives, formulation auxiliaries or detergents.
10. The use of the compounds as claimed in one or more of claims 1 to 3 for the production of a medicament for influencing the enterohepatic circulation of the bile acids.
11. The use of the compounds as claimed in one or more of claims 1 to 3 for the production of a medicament for influencing lipid absorption.
12. The use of the compounds as claimed in one or more of claims 1 to 3 for the production of a medicament for influencing the serum cholesterol level.
13. The use of the compounds as claimed in one or more of claims 1 to 3 for the production of a medicament for the concentration-dependent inhibition of bile acid absorption in the gastrointestinal tract.
14. The use of the compounds as claimed in one or more of claims 1 to 3 for the production of a medicament for the prevention of arteriosclerotic symptoms.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19633268.0 | 1996-08-19 | ||
| DE19633268A DE19633268A1 (en) | 1996-08-19 | 1996-08-19 | Polymeric bile acid absorption inhibitors with simultaneous bile acid adsorber action |
| PCT/EP1997/004049 WO1998007449A2 (en) | 1996-08-19 | 1997-07-25 | Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2263671A1 true CA2263671A1 (en) | 1998-02-26 |
Family
ID=7802940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002263671A Abandoned CA2263671A1 (en) | 1996-08-19 | 1997-07-25 | Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0918544A2 (en) |
| JP (1) | JP2000517356A (en) |
| CA (1) | CA2263671A1 (en) |
| DE (1) | DE19633268A1 (en) |
| WO (1) | WO1998007449A2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11685835B2 (en) | 2016-05-11 | 2023-06-27 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
| US11827661B2 (en) | 2015-02-26 | 2023-11-28 | Sony Group Corporation | Water soluble fluorescent or colored dyes comprising conjugating groups |
| US11874280B2 (en) | 2018-03-19 | 2024-01-16 | Sony Group Corporation | Use of divalent metals for enhancement of fluorescent signals |
| US11931419B2 (en) | 2017-11-16 | 2024-03-19 | Sony Group Corporation | Programmable polymeric drugs |
| US11939474B2 (en) | 2013-08-22 | 2024-03-26 | Sony Group Corporation | Water soluble fluorescent or colored dyes and methods for their use |
| US11945955B2 (en) | 2019-09-26 | 2024-04-02 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3942846B2 (en) * | 2001-06-21 | 2007-07-11 | 独立行政法人科学技術振興機構 | Tissue-specific transporter inhibitor |
| JPWO2004035817A1 (en) * | 2002-10-16 | 2006-02-16 | 協和メデックス株式会社 | Method and reagent for measuring cholesterol in high density lipoprotein |
| PT2637646T (en) | 2010-11-08 | 2016-08-17 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| SG190029A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
| JO3301B1 (en) | 2013-04-26 | 2018-09-16 | Albireo Ab | Crystal modifications of elobixibat |
| KR102560954B1 (en) | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | Solid preparation, and method for preventing or reducing discoloration thereof |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| JP6954926B2 (en) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | Oral cholestyramine preparation and its use |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| EP3413878B1 (en) | 2016-02-09 | 2021-04-14 | Albireo AB | Oral cholestyramine formulation and use thereof |
| CN110996915B (en) | 2017-08-09 | 2023-10-03 | 阿尔比里奥公司 | Cholestyramine pellet, oral cholestyramine preparation and application thereof |
| CN111032019B (en) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | Cholestyramine granules, oral cholestyramine preparation and application thereof |
| CN111465608A (en) * | 2017-12-13 | 2020-07-28 | 索尼公司 | Ionic polymers comprising biologically active compounds |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| CA3100691A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| RS63899B1 (en) | 2019-02-06 | 2023-02-28 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| JP2022519664A (en) | 2019-02-06 | 2022-03-24 | アルビレオ・アクチボラグ | Benzodiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021110885A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| JP2023504645A (en) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023504647A (en) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202134220A (en) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN114761080A (en) | 2019-12-04 | 2022-07-15 | 阿尔比里奥公司 | Benzothia (di) azepin compounds and their use as bile acid modulators |
| AR120674A1 (en) | 2019-12-04 | 2022-03-09 | Albireo Ab | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID |
| PT4069360T (en) | 2019-12-04 | 2024-03-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| AR120683A1 (en) | 2019-12-04 | 2022-03-09 | Albireo Ab | BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID |
| JP2023537285A (en) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572985D1 (en) * | 1984-05-11 | 1989-10-19 | Bristol Myers Co | Novel bile sequestrant resin and uses |
| FI106800B (en) * | 1990-12-06 | 2001-04-12 | Hoechst Ag | A process for the preparation of novel therapeutically useful dimeric bile acid derivatives |
| AU653658B2 (en) * | 1991-12-20 | 1994-10-06 | Hoechst Aktiengesellschaft | Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals |
| AU664059B2 (en) * | 1991-12-20 | 1995-11-02 | Hoechst Aktiengesellschaft | Ethylenically unsaturated bile acid derivatives, processes for their preparation and precursors |
| DK0580078T3 (en) * | 1992-07-22 | 1998-05-25 | Hoechst Ag | Polyvinylamine derivatives with hydrophilic centers, process for their preparation as well as the use of the compounds as drugs, carriers of active substances and food aid. |
| ES2096150T3 (en) * | 1992-07-22 | 1997-03-01 | Hoechst Ag | LINKED VINYL COPOLYMERS, PROCEDURE FOR THEIR PREPARATION, AS WELL AS THE USE OF THESE COMPOUNDS. |
| DE4234537A1 (en) * | 1992-10-14 | 1994-04-21 | Hoechst Ag | A compound a polymeric bile acid and insulin - useful in the prodn. of a medicament for diabetes mellitus, for nasal admin. |
| JPH06321785A (en) * | 1993-05-12 | 1994-11-22 | Sekisui Chem Co Ltd | Enteroabsorption inhibitor for bile acid |
| JPH06329543A (en) * | 1993-05-20 | 1994-11-29 | Sekisui Chem Co Ltd | Peroral cholesterol lowering agent |
| US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
-
1996
- 1996-08-19 DE DE19633268A patent/DE19633268A1/en not_active Withdrawn
-
1997
- 1997-07-25 EP EP97940028A patent/EP0918544A2/en not_active Withdrawn
- 1997-07-25 CA CA002263671A patent/CA2263671A1/en not_active Abandoned
- 1997-07-25 WO PCT/EP1997/004049 patent/WO1998007449A2/en not_active Application Discontinuation
- 1997-07-25 JP JP10510319A patent/JP2000517356A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11939474B2 (en) | 2013-08-22 | 2024-03-26 | Sony Group Corporation | Water soluble fluorescent or colored dyes and methods for their use |
| US11827661B2 (en) | 2015-02-26 | 2023-11-28 | Sony Group Corporation | Water soluble fluorescent or colored dyes comprising conjugating groups |
| US11685835B2 (en) | 2016-05-11 | 2023-06-27 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
| US11931419B2 (en) | 2017-11-16 | 2024-03-19 | Sony Group Corporation | Programmable polymeric drugs |
| US11874280B2 (en) | 2018-03-19 | 2024-01-16 | Sony Group Corporation | Use of divalent metals for enhancement of fluorescent signals |
| US11945955B2 (en) | 2019-09-26 | 2024-04-02 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000517356A (en) | 2000-12-26 |
| WO1998007449A3 (en) | 1998-06-25 |
| WO1998007449A2 (en) | 1998-02-26 |
| EP0918544A2 (en) | 1999-06-02 |
| DE19633268A1 (en) | 1998-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2263671A1 (en) | Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect | |
| JP6247740B2 (en) | Cross-linked polyvinylamine, polyallylamine and polyethyleneimine for use as bile acid scavengers | |
| KR100271693B1 (en) | Process for removing bile salts from a patient and alkylated composition used for the process | |
| JP4499363B2 (en) | Method for reducing serum glucose | |
| CA2303447C (en) | Cationic polymers as toxin-binding agents | |
| CA2117371C (en) | Cholesterol-lowering drug | |
| JPH0625354A (en) | Polymer and oligomer of bile acid derivative, their production, and their use as medicine | |
| JPH06192129A (en) | Bile acid sealing agent | |
| CN103145932A (en) | Long-circulating anti-tumor targeting drug carrier and preparation method thereof | |
| AU728985B2 (en) | Crosslinked vinyl polymers having bile acid adsorber action | |
| US5114709A (en) | Ferric ion coordinated polyamine resins for the lowering of blood cholesterol | |
| CA2063499C (en) | Ingestible polymeric phosphonium salts for the lowering of blood cholesterol | |
| CA3046541A1 (en) | Biocompatible and hydrophilic polymer conjugate for targeted delivery of an agent | |
| MXPA99001725A (en) | Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect | |
| Thale et al. | Binding of bile acids to anion-exchanging drugs in vitro | |
| CA1335142C (en) | Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol | |
| DE19748659A1 (en) | Aminophosphonium group-containing crosslinked copolymers for medical uses | |
| JP2003147025A (en) | Bile acid specific recognition polymer and cholesterol- lowering agent | |
| DE19748712A1 (en) | Polymers containing aminophosphonium groups | |
| Güler | DRUG DELIVERY PLATFORM FOR TARGETING OSTEOSARCOMA | |
| MXPA99007600A (en) | Cross-linked vinyl polymers with bile acid adsorbing effect | |
| CN104337767A (en) | Method for preparing pH sensitive drug carrier micelle | |
| Zhu et al. | Polymeric Sorbents for Bile Acids: II. Oligopeptide-Containing Resins with Quaternary Amine Groups | |
| JPWO2021084087A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |